MODIFIED PARVOVIRUS HAVING ENHANCED ANTI-TUMOR EFFICACY

Described are parvovirus variants derived, e.g., from H-1PV, showing higher anti-tumor potential compared to the wild type parvovirus, wherein said variant is characterized by (a) an amino acid substitution, alteration or addition, preferably substitution at position Lys96 of NS-2 and/or position Leu103 of NS-2 (together with a amino acid substituion at position Tyr595 of NS-1 in the latter case), or (b) an in-frame deletion in the parvovirus genome, preferably a deletion resulting in a large amino acid deletion in both the central part (aa 96-133) of NS-2 and the C-terminal part (aa 587-624) of NS-1. The present invention also relates to the use of said parvovirus variants for cancer therapy. 1. A parvovirus variant showing higher anti-tumor potential compared to the wild type parvovirus , wherein said variant is characterized by (a) an amino acid substitution , deletion or addition at position Lys96 of NS-2 and/or position Leu103 of NS-2 , or (b) an in-frame deletion in the left-hand part of the parvovirus genome affecting both the central part of NS2 and the C-terminal part of the NS1 protein sequences.2. The parvovirus variant of claim 1 , wherein said variant is characterized by amino acid substitution(s) claim 1 , or said variant is characterized by an in-frame deletion from nt 2022 to 2135 resulting in the translation of an NS1 protein having a deletion of aa 587-624 and an NS2 protein having a deletion of aa 96-133.3. The parvovirus variant of claim 2 , wherein Lys at position 96 of NS-2 is replaced by an hydrophilic polar amino acid and/or Leu at position 103 of NS-2 is replaced by a neutral nonpolar amino acid.4. The parvovirus variant of claim 3 , comprising the following amino acid substitution(s) Lys96Glu and/or Leu103Pro of NS-2.5. The parvovirus variant of claim 4 , comprising the following substitution(s):(a) Lys96Glu of NS2; or(b) Leu103Pro of NS2 and Tyr595His of NS1.6. The parvovirus variant of claim 1 , which is derived from parvovirus H-1 (H-1PV ...

MONOCLONAL ANTIBODIES AGAINST ORTHOPOXVIRUSES

The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. 1. A substantially pure polypeptide comprising a fully human or humanized chimpanzee monoclonal antibody that binds A33 antigen , wherein said monoclonal antibody comprises a heavy chain CDR1 region having the amino acid sequence of SEQ ID NO:67 , a heavy chain CDR2 region having the amino acid sequence of SEQ ID NO:69 , a heavy chain CDR3 region having the amino acid sequence of SEQ ID NO:71 , a light chain CDR1 region having the amino acid sequence of SEQ ID NO:75 , a light chain CDR2 region having the amino acid sequence of SEQ ID NO:77 and a light chain CDR3 region having the amino acid sequence of SEQ ID NO:79.23-. (canceled)4. A substantially pure polypeptide comprising a monoclonal antibody that binds the antigen to which anti-vaccinia virus A33 12F protein Fab fragment deposited with the ATCC as ATCC Accession No. PTA-7324 binds.5. The substantially pure polypeptide of wherein said antibody comprises a Fd fragment.6. The substantially pure polypeptide of wherein said antibody comprises a Fab fragment.721-. (canceled)22. An anti-vaccinia virus A33 12F deposited with ATCC as ATCC Accession No. PTA-7324.23. A pharmaceutical preparation comprising the monoclonal antibody of .24. A diagnostic preparation comprising the monoclonal antibody of .25. A method for inhibiting Orthopoxvirus infection comprising:{'claim-ref': {'@idref': 'CLM-00023', 'claim 23'}, ' ...

REARRANGED TT VIRUS MOLECULES FOR USE IN DIAGNOSIS, PREVENTION AND TREATMENT OF CANCER AND AUTOIMMUNITY

The present invention relates to rearranged molecules of (a) a specific TT virus sequence and (b) a nucleotide sequence encoding a polypeptide showing homology to mammalian proteins associated with cancer and autoimmune diseases that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity. 1. A rearranged TT virus polynucleic acid comprising{'figref': {'@idref': 'DRAWINGS', 'FIG. 6'}, '(a) a nucleotide sequence shown in ;'}(b) a nucleotide sequence which shows at least 70% identity to a nucleotide sequence of (a) and is capable of replicating autonomously and/or inducing autonomous replication;(c) a fragment of a nucleotide sequence of (a) or (b) which is capable of replicating autonomously;(d) a nucleotide sequence which is the complement of the nucleotide sequence of (a), (b), or (c); or(e) a nucleotide sequence which is redundant as a result of the degeneracy of the genetic code compared to any of the above-given nucleotide sequences.2. The rearranged TT virus polynucleic acid of consisting of{'figref': {'@idref': 'DRAWINGS', 'FIG. 6'}, '(a) a nucleotide sequence shown in ;'}(b) a nucleotide sequence which shows at least 70% identity to a nucleotide sequence of (a) and is capable of replicating autonomously and/or inducing autonomous replication;(c) a fragment of a nucleotide sequence of (a) or (b) which is capable of replicating autonomously;(d) a nucleotide sequence which is the complement of the nucleotide sequence of (a), (b), or (c); or(e) a nucleotide sequence which is redundant as a result of the degeneracy of the genetic code compared to any of the above-given nucleotide sequences.3. The rearranged TT virus polynucleic acid of claim 1 , wherein said nucleotide sequence of (a) claim 1 , (b) claim 1 , (c) claim 1 , (d) or (e) is linked to a polynucleic acid encoding a polypeptide containing a signature motif of a mammalian protein or allergen being associated with cancer or an ...

HIGHLY POTENT PEPTIDES TO CONTROL CANCER AND NEURODEGENERATIVE DISEASES

This invention provides compositions and method of diminishing or inhibiting autophagy by administering a FLIP protein that binds to Atg3, interfering with the formation of the LC3-Atg4-Atg7-Atg3 conjugation complex necessary for autophagy induction. This invention also provides FLIP peptide fragments that promote or induce autophagy by interfering with the activity of FLIP. 1. A method for increasing or inducing the death of a cancer cell comprising administering to the cell an effective amount of one or more of: a FLIP peptide fragment , variant , hybrid or biological equivalent thereof , an amino acid comprising SEQ ID. NOS. 1 through 8 , 15 through 18 , 41 through 47 or a biological equivalent of each thereof , a FLIP peptide fragment isolated from a FLIP protein death effector domain region of the FLIP protein or from a portion of the death effector domain region of the FLIP protein , a FLIP peptide fragment isolated from an alpha-helix fragment of the FLIP protein death effector domain region or from a portion of the alpha-helix fragment of the FLIP protein death effector domain region , or a peptide selected from one or more of:(a) an isolated or recombinant peptide comprising one or more peptide shown in SEQ ID NO. 41 through 47, or an amino acid sequence having at least 80% homology to an amino acid sequence of SEQ ID NO. 41 to 47, wherein amino acid 5 and/or 6 is Lor W, respectively;(b) an isolated or recombinant variant peptide comprising an amino acid sequence selected from SEQ ID NOS. 2, 4, 6 or 8, having a substitution with 1, 2, 3, or 4 amino acids at the corresponding positions of the a region of one or more other peptides selected from SEQ ID NOS. 2, 4, 6 or 8;(c) an isolated or recombinant peptide comprising a hybrid peptide between any two amino acid sequences selected from SEQ ID NO.2, 4, 6 or 8 or a peptide having at least 80% homology to the hybrid peptide;(d) an isolated or recombinant hybrid peptide comprising anN-terminal amino acid sequence ...

Isolation, Cloning and Characterization of New Adeno-Associated Virus (AAV) Serotypes

The present invention provides new adeno-associated virus (AAV) viruses and vectors, and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV vectors and particles. 1113-. (canceled)114. An isolated nucleic acid molecule comprising a nucleic acid sequence comprising at least 100 contiguous nucleotides from an AAV-X1 virus.115. The isolated nucleic acid molecule of claim 114 , wherein the nucleic acid sequence encodes an immunogenic portion of a protein selected from the group consisting of an AAV-X1 REP and an AAV-X1 CAP protein.116. The isolated nucleic acid molecule of claim 115 , wherein the AAV-X1 REP protein is selected from the group consisting of AAV-X1 REP40 claim 115 , AAV-X1 REP52 claim 115 , AAV-X1 REP68 and AAV-X1 REP78.117. The isolated nucleic acid molecule of claim 115 , wherein the AAV-X1 CAP protein is selected from the group consisting of AAV-X1 VP1 claim 115 , AAV-X1 VP2 and AAV-X1 VP3.118. The isolated nucleic acid molecule of claim 114 , wherein the nucleic acid sequence encodes a protein comprising at least 50 contiguous amino acids from SEQ ID NO: 21 or SEQ ID NO:49.119. The isolated nucleic acid molecule of claim 114 , wherein the nucleic acid sequence is selected from the group consisting of:a) a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence at least 80% identical to SEQ ID NO:21, wherein the polypeptide binds an antibody raised against a protein consisting of SEQ ID NO:21; and,b) a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence at least 80% identical to SEQ ID NO:49, wherein the polypeptide binds an antibody raised against a protein consisting of SEQ ID NO:49.120. The isolated nucleic acid molecule of claim 114 , wherein the nucleic acid sequence is selected from the group consisting of:a) a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence at least 95% identical to ...

NOVEL POLYMAVIRUS ASSOCIATED WITH DIARRHEA IN CHILDREN

Provided is a new polyomavirus, provisionally named MX polyomavirus, (MXPyV). Further provided are cDNA nucleic acid sequences, recombinant proteins, expression vectors and host cells, recombinant anti-MXPyV antibodies, vaccines, compositions, methods of detecting MXPyV, methods for assaying for anti-MXPyV compounds, and methods for treating or preventing a MXPyV infection. 1. A cDNA molecule comprising a nucleotide sequence of at least 100 nucleotides in length , wherein said sequence has at least 90% sequence identity to a portion of the same length in SEQ ID NO:1 or its complement.2. The cDNA molecule of claim 1 , wherein said sequence has at least 95% identity to a portion of the same length in SEQ ID NO:1 or its complement.3. The cDNA molecule of claim 1 , wherein said sequence has 100% identity to a portion of the same length in SEQ ID NO:1 or its complement.4. The cDNA molecule of claim 1 , wherein the nucleotide sequence comprises at least 90% identity over the full length of SEQ ID NO:1 or its complement.5. The cDNA molecule of claim 1 , wherein the nucleotide sequence comprises at least 95% identity over the full length of SEQ ID NO:1 or its complement.6. The cDNA molecule of claim 1 , wherein the nucleotide sequence comprises SEQ ID NO:1.7. An isolated expression vector comprising the cDNA molecule of .8. An isolated host cell comprising the expression vector of .9. An cDNA molecule comprising a nucleotide sequence of at least 100 nucleotides in length claim 6 , said sequence having at least 90% sequence identity to an open reading frame selected from the group consisting of SEQ ID NOs:2-7.10. The cDNA molecule of claim 9 , wherein the nucleotide sequence has at least 95% identity to the open reading frame selected from the group consisting of SEQ ID NOs:2-7.11. The cDNA molecule of claim 9 , wherein the nucleotide sequence has an open reading frame selected from the group consisting of SEQ ID NOs:2-7.12. A recombinant peptide encoded by the cDNA molecule ...

BI-Specific Diabodies For Masking And Targeting Vaccines

The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response. In other embodiments, vectors that recruit and activate specific antigen-presenting cells may further enhance the efficacy of those immune responses.

Treatment of amd using aav sflt-1

The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.

ANTHRAX AND SMALL POX REPLIKINS AND METHODS OF USE

Isolated peptides of the Anthrax Toxin Lethal factor Protein pX01-107, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Anthrax Toxin Lethal factor Protein pX01-107 are disclosed. Also disclosed are isolated peptides of the Small Pox Virus Surface Antigen S Precursor Protein, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Small Pox Virus Surface Antigen S Precursor Protein. 127-. (canceled)28. An isolated antibody that specifically binds to a small pox virus peptide sequence consisting of 7 to about 50 amino acids with at least one lysine residue on one end of the peptide sequence and at least one lysine residue or at least one histidine residue on the other end of the peptide sequence , wherein the peptide sequence comprises:(1) at least one lysine residue located six to ten amino acid residues from a second lysine residue;(2) at least one histidine residue; and(3) at least 6% lysine residues.29. An antibody cocktail comprising a plurality of isolated antibodies of .30. A composition comprising the isolated antibody of and a pharmaceutically acceptable carrier and/or adjuvant.31. A composition comprising the antibody cocktail of and a pharmaceutically acceptable carrier and/or adjuvant.32. The isolated antibody of wherein the n-terminus of said small pox virus peptide sequence is a lysine residue and the c-terminus of said small pox virus peptide sequence is a lysine residue.33. The isolated antibody of wherein the n-terminus of small pox virus peptide sequence is a histidine residue and the c-terminus of said small pox virus peptide sequence is a lysine residue.34. The isolated antibody of wherein the n-terminus of said small pox virus peptide sequence is a lysine residue and the c-terminus of said small pox virus peptide sequence is a histidine residue.35. The isolated antibody of or wherein said small pox ...

Biological Therapeutics for Infection-Relating Disorders or Conditions

The present invention discloses products and the methods of uses of the products for preventing and treating infectious diseases and the disorders or conditions inducible by harmful antibodies. The harmful antibodies are induced during infection, or vaccination, or use of therapeutic antibodies. The products of the present disclosure comprise immunoglobulin products, serum or plasma, specific antibodies to viral pathogens. 1. A method of treating or preventing infection by a viral pathogen , comprising administering an effective amount of immunoglobulin product , serum , or plasma to a patient who has been diagnosed with infection by the viral pathogen or who is at risk for infection by the viral pathogen , wherein the immunoglobulin product , the serum , or the plasma is obtained from a healthy individual.2. The method of claim 1 , wherein the viral pathogen is an influenza virus claim 1 , a hepatitis C virus claim 1 , a hepatitis B virus claim 1 , a respiratory syncytial virus claim 1 , an adenovirus claim 1 , or a rotavirus.3. The method of claim 2 , wherein the influenza virus is 2009 H1N1 (swine flu) claim 2 , B influenza virus claim 2 , H5N1 (avian flu) claim 2 , H1N1 claim 2 , or H3N2.4. The method of claim 1 , wherein the effective amount of the immunoglobulin product is between about 0.001 grams to about 100 grams.5. The method of claim 1 , wherein the effective amount of the serum or the plasma is between about 0.1 ml to about 1000 ml.6. The method of claim 1 , wherein the immunoglobulin product claim 1 , the serum claim 1 , or the plasma is in the form of a solution claim 1 , a lyophilized claim 1 , an injectable claim 1 , an infusion claim 1 , or a form conjugated to a nano-particle.7. The method of claim 1 , wherein the immunoglobulin product is provided in a composition comprising N-acetylneuraminic acid claim 1 , an analog of N-acetylneuraminic acid claim 1 , N-acetylneuraminic acid methyl ester claim 1 , N-acetylneuraminic acid and an analog of N- ...

PORCINE CIRCOVIRUS TYPE 3 IMMUNOGENIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME

A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions. 1. A vector comprising:at least one heterologous nucleic acid sequence encoding a first porcine circovirus type 3 (PCV3) protein.2. The vector of claim 1 , wherein the PCV3 protein is selected from the group consisting of ORF1 claim 1 , ORF2 claim 1 , ORF3 claim 1 , and any combination thereof.3. The vector of claim 2 , wherein the PCV3 protein has at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NO. 4 claim 2 , SEQ ID NO. 6 claim 2 , or SEQ ID NO. 8.4. The vector of claim 1 , wherein the heterologous nucleic acid sequence has at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID. NO. 3 claim 1 , SEQ ID NO. 5 claim 1 , or SEQ ID NO. 7.5. The vector of claim 1 , wherein the vector is a transfer vector.6. The vector of claim 1 , wherein the vector is a viral vector or a plasmid.7. The vector of claim 1 , wherein the vector comprises a transfer vector that has been transfected into a viral vector.8. The vector of claim 6 , wherein the viral vector is a baculovirus vector.9. The vector of claim 1 , further comprising at least one additional nucleic acid sequence that allows the cloning of said heterologous nucleic acid sequence into said vector.10. The vector of claim 9 , wherein said at least one further nucleic acid sequence flanks said heterologous nucleic acid sequence.11. The vector of claim 9 , wherein said additional nucleic acid sequence is homologous with at least part of said heterologous nucleic acid sequence.12. The vector of claim 9 , wherein said additional ...

Novel System for the Biocontrol of Pathogens in Aquaculture and Other Animal Systems

The inventive technology relates to novel paratransgenic strategies for the biocontrol of pathogens in animal systems using interfering RNA molecules expressed in genetically modified bacteria that may be configured to colonize a target host. In one preferred embodiment, the invention includes novel paratransgenic strategies for the biocontrol of pathogens in aquatic organisms raised in aquaculture environments. 17-. (canceled)8. A genetically modified probiotic bacteria configured for the biocontrol of white spot syndrome virus in shrimp comprising:a genetically modified probiotic enteric bacteria that expresses at least one heterologous inhibitory polynucleotide selected from the group consisting of: SEQ ID NO. 1, SEQ ID NO. 2, and/or SEQ ID NO. 3, wherein said at least one heterologous inhibitory polynucleotide is double stranded RNA polynucleotide molecule (dsRNA) that targets an essential gene in a white spot syndrome virus, and wherein said genetically modified probiotic enteric bacteria is configured to be probiotic to shrimp.9Bacillus subtilis. A genetically modified probiotic bacteria configured for the biocontrol of white spot syndrome virus in shrimp as described in wherein said genetically modified probiotic enteric bacteria comprises a genetically modified bacteria.10Bacillus subtilisBacillus subtilis. A genetically modified probiotic bacteria configured for the biocontrol of white spot syndrome virus in shrimp as described in wherein said genetically modified bacteria comprises an RNaseIII deficient genetically modified bacteria.11. A genetically modified probiotic bacteria configured for the biocontrol of white spot syndrome virus in shrimp as described in wherein said essential gene in a white spot syndrome virus comprises an essential gene in a white spot syndrome virus selected from the group consisting of: the vp28 gene claim 10 , the vp19 gene claim 10 , or the wsv477 gene.12. A genetically modified probiotic bacteria configured for the ...

ADENOVIRUSES AND THEIR USE

Baboon Adenovirus (BaAdV)-2/4 and BaAdV-3 are disclosed herein. BaAdV-2/4 and BaAdV-3 polynucleotide, polypeptides and antibodies that specifically bind BaAdV-2/4 and/or BaAdV-3 are disclosed. Methods are disclosed for detecting BaAdV-2/4 and BaAdV-3. Methods are also disclosed for treating, preventing, and inducing an immune response to BaAdV-2/4 and/or BaAdV-3. Kits are also provided. 1. An isolated recombinant nucleic acid molecule comprising a nucleic acid sequence at least 100 nucleotides in length that has at least 90% sequence identity over its length to SEQ ID NO:1 , SEQ ID NO: 2 , SEQ ID NO: 3 , or the complement thereof , wherein the recombinant nucleic acid is:(a) a cDNA;(b) attached to a detectable label; or(c) operably linked to a heterologous nucleic acid.2. An isolated recombinant isolated nucleic acid molecule comprising:(a) a nucleic acid sequence at least 90% identical to nucleotides 1-29685 and 29867-34391 of the nucleic acid sequence set forth as SEQ ID NO: 1;(b) a nucleic acid sequence at least 90% identical to nucleotides 1-29865 and 29867-34391 of the nucleic acid sequence set forth as SEQ ID NO: 2;(c) a nucleotide sequence at least 90% identical to the nucleotide sequence set forth as nucleotides 1-28677 and 29812-34402 of SEQ ID NO: 3.3. The isolated recombinant nucleic acid molecule of claim 2 , comprising the nucleic acid sequence set forth as SEQ ID NO: 1 claim 2 , SEQ ID NO: 2 claim 2 , SEQ ID NO: 3 or a degenerate variant thereof.4. A cDNA comprising a nucleic acid sequence at least 90% identical to an open reading frame of SEQ ID NO 1 claim 2 , SEQ ID NO: 2 or SEQ ID NO: 3.5. The cDNA of claim 4 , comprising an open reading frame of the nucleic acid sequence set forth as SEQ ID NO: 1 claim 4 , SEQ ID NO: 2 or SEQ ID NO: 3.6. An isolated polypeptide encoded by the nucleic acid sequence of .7. The isolated polypeptide of claim 6 , comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth as one of SEQ ...

RECOMBINANT HUMAN ANTIBODIES FOR THERAPY AND PREVENTION OF POLYOMAVIRUS-RELATED DISEASES

Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics. 129-. (canceled)30. A polynucleotide encoding at least a binding domain of a variable region of an immunoglobulin chain of a human monoclonal antibody or an antigen-binding fragment thereof capable of binding to a polyomavirus and/or antigen thereof.31. A vector comprising the polynucleotide of .32. The vector of claim 31 , further comprising a polynucleotide encoding at least a binding domain of a variable region of an immunoglobulin chain of a human monoclonal antibody or an antigen-binding fragment thereof capable of binding to a polyomavirus and/or antigen thereof claim 31 , wherein the polyomavirus is JC virus (JCV) or BK virus (BKV) claim 31 , wherein the polynucleotide further encodes the variable region of the other immunoglobulin chain of the antibody or an antigen-binding fragment thereof.33. A host cell comprising a polynucleotide of .34. A composition comprising a polynucleotide of .35. The composition of claim 34 , wherein the composition:(a) is a pharmaceutical composition and further comprises a pharmaceutical acceptable carrier, or(b) is a diagnostic composition, and further comprises reagents conventionally used in immune- or nucleic acid based diagnostic methods.36. The composition of claim 34 , further comprising an immunomodulatory agent.37. A kit useful in the diagnosis or monitoring of the progression of ...

METHODS TO DIAGNOSE AND IMMUNIZE AGAINST THE VIRUS CAUSING HUMAN MERKEL CELL CARCINOMA

The present invention provides murine monoclonal antibody molecules that bind to Merkel cell carcinoma (MCV) polypeptides. 1. An isolated or substantially purified murine monoclonal antibody molecule that binds selectively to a polypeptide consisting essentially of an amino acid sequence selected from the group of sequences consisting of SEQ ID NOs: 12 and 14. This patent application is a continuation of U.S. patent application Ser. No. 13/951,679 filed Jul. 26, 2013, now U.S. Pat. No. 9,156,888. U.S. patent application Ser. No. 13/951,679 is a divisional of U.S. patent application Ser. No. 12/808,042 filed Jan. 21, 2011, now U.S. Pat. No. 8,524,248, and which is a U.S. National Phase of International Patent Application No. PCT/US08/86895, filed Dec. 15, 2008. This patent application claims the benefit of U.S. Provisional Patent Application No. 61/013,772 filed Dec. 14, 2007. The contents of each of these prior applications are incorporated by reference.This invention was made with Government support under Grant Number NIH R33CA120726 awarded by the National Institutes of Health. The Government has certain rights in this invention.Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 107,784 Byte ASCII (Text) file named “721583 ST25.TXT” created on Sep. 22, 2015.The present invention provides isolated or substantially purified polypeptides, nucleic acids, and virus-like particles (VLPs) derived from a Merkel cell carcinoma virus (MCV), which is a newly-discovered virus. The invention further provides monoclonal antibody molecules that bind to MCV polypeptides. The invention further provides diagnostic, prophylactic, and therapeutic methods relating to the identification, prevention, and treatment of MCV-related diseases. These aspects, and other inventive features, will be apparent upon reading the following detailed description in conjunction with ...

PROPHYLACTIC VACCINE AGAINST EGG DROP SYNDROME (EDS)

The present invention is intended to provide an egg drop syndrome (EDS) vaccine that is capable of effectively preventing EDS and can be stably supplied. The EDS vaccine provided to this end contains as an active ingredient fused protein in which a polypeptide having a coiled-coil forming unit is bound to the knob region in the fiber protein of EDS virus (EDSV). 1. A fused protein in which a polypeptide having a coiled-coil forming unit is bound to a Knob region in a fiber protein of egg drop syndrome (EDS) virus (EDSV).2. The fused protein according to claim 1 , comprising a linker sequence claim 1 , a tag sequence claim 1 , or both claim 1 , between the polypeptide and the Knob.3. The fused protein according to claim 1 , wherein the coiled-coil forming unit is derived from a native multimer-forming protein.4. The fused protein according to claim 3 , wherein the native multimer-forming protein is a GCN4 or a cartilage matrix protein (CMP).5. The fused protein according to claim 4 , wherein the GCN4 or the CMP is bound to the C-terminal side of the Knob.6. The fused protein according to claim 5 , wherein the GCN4 is bound to the C-terminal side of the Knob.7. The fused protein according to claim 6 , comprising a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 13 claim 6 , or a polypeptide consisting of an amino acid sequence of SEQ ID NO: 13 with the deletion claim 6 , substitution claim 6 , or addition of one or several amino acids.8. The fused protein according to claim 5 , wherein the CMP is bound to the C-terminal side of the Knob.9. The fused protein according to claim 8 , comprising a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 23 claim 8 , or a polypeptide consisting of an amino acid sequence of SEQ ID NO: 23 with the deletion claim 8 , substitution claim 8 , or addition of one or several amino acids.10. The fused protein according to claim 4 , wherein the GCN4 or the CMP is bound to the N-terminal ...

MONOCLONAL ANTIBODIES SPECIFIC FOR THE PIII ANTIGEN OF HUMAN ADENOVIRUS (ADV), PRODUCED AND SECRETED BY CELL HYBRIDOMAS, USEFUL FOR DETECTION AND DIAGNOSIS OF ADV INFECTION

The present invention refers to monoclonal antibodies, or fragments thereof, which recognize the pIII protein of the Adenovirus (ADV), useful for developing diagnostic methods of ADV infection in humans. Particularly, it refers to a monoclonal antibody or fragment thereof comprising a variable region of the heavy chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID No: 5 and a variable region of the light chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 2 or SEQ ID No: 6. It also is addressed to the nucleotide sequences which define said antibodies, in vitro and/or ex vivo diagnostic methods of ADV infection in a biological sample using said monoclonal antibodies, and diagnostic kits for detecting ADV comprising at least one monoclonal antibody against ADV according to the above description. 1. Monoclonal antibody or a fragment thereof which binds to the pIII protein of Adenovirus (ADV) comprising a variable region of the heavy chain having a sequence with at least a 90% , 95% or 99% of identity with the SEQ ID No:1 or SEQ ID No: 5 and a variable region of the light chain having a sequence with at least a 90% , 95% or 99% of identity with the SEQ ID No:2 or SEQ ID No:6.2. Monoclonal antibody or fragment thereof claim 1 , according to claim 1 , wherein the antibody or fragment thereof is also bound to a label selected from the group consisting of fluorophores claim 1 , biotin claim 1 , radioisotopes claim 1 , metals claim 1 , proteins claim 1 , enzymes claim 1 , or any other chemical compound.3. Set of nucleotide sequences codifying a monoclonal antibody or a fragment thereof claim 1 , according to claim 1 , comprising a sequence with at least 80% claim 1 , 85% claim 1 , 90% claim 1 , 95% and 99% of identity with the SEQ ID No: 3 claim 1 , or SEQ ID No: 7 claim 1 , and their reverse complement claim 1 , which codifies the variable region of the heavy chain of the antibody and ...

PORCINE PARVOVIRUS

The present invention relates to a novel porcine parvovirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Further the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus. 126-. (canceled)27. An isolated virus which is a member of the sub-family Parvovirinae of the family of the Parvoviridae , said virus being characterized in that:a) the virus is an haemorrhagic bowel syndrome (HBS)-associated virus; andb) the virus has a viral genome comprising a gene encoding a Capsid Protein (CP) and a gene encoding a non-structural protein 1 (NS1), wherein the nucleotide sequence of the CP gene has at least 80% identity to the nucleotide sequence of SEQ ID NO: 1 or the nucleotide sequence of the NS1 gene has at least 80% identity to the nucleotide sequence of SEQ ID NO: 3.28. The isolated virus of claim 27 , wherein the nucleotide sequence of the CP gene has at least 80% identity to the nucleotide sequence of SEQ ID NO: 1 and the nucleotide sequence of the NS1 gene has at least 80% identity to the nucleotide sequence of SEQ ID NO: 3.29. An isolated virus which is a member of the sub-family Parvovirinae of the family of the Parvoviridae claim 27 , said virus being characterized in that:a) the virus is an HBS-associated porcine parvovirus; andb) the viral genomic DNA reacts in a PCR reaction with a primer set of SEQ ID NO: 5 and SEQ ID NO: 6 to give a PCR product of 140+/−10 base pairs or reacts in a PCR reaction with a primer set of SEQ ID NO: 7 and SEQ ID NO: 8 to give a PCR product of 853+/−10 base pairs.30. The isolated virus of claim 29 , wherein the viral genomic DNA reacts in a PCR reaction with a primer set of SEQ ID NO: 5 and SEQ ID NO: 6 to give a PCR product of 140+/−10 base pairs and reacts in a PCR ...

ADENOVIRUSES AND THEIR USE

Baboon Adenovirus (BaAdV)-2/4 and BaAdV-3 are disclosed herein. BaAdV-2/4 and BaAdV-3 polynucleotide, polypeptides and antibodies that specifically bind BaAdV-2/4 and/or BaAdV-3 are disclosed. Methods are disclosed for detecting BaAdV-2/4 and BaAdV-3. Methods are also disclosed for treating, preventing, and inducing an immune response to BaAdV-2/4 and/or BaAdV-3. Kits are also provided. 1. An isolated recombinant nucleic acid molecule comprising a nucleic acid sequence at least 100 nucleotides in length that has at least 90% sequence identity over its length to SEQ ID NO:1 , SEQ ID NO: 2 , SEQ ID NO: 3 , or the complement thereof , wherein the recombinant nucleic acid is:(a) a cDNA;(b) attached to a detectable label; or(c) operably linked to a heterologous nucleic acid.2. An isolated recombinant isolated nucleic acid molecule comprising:(a) a nucleic acid sequence at least 90% identical to nucleotides 1-29685 and 29867-34391 of the nucleic acid sequence set forth as SEQ ID NO: 1;(b) a nucleic acid sequence at least 90% identical to nucleotides 1-29865 and 29867-34391 of the nucleic acid sequence set forth as SEQ ID NO: 2;(c) a nucleotide sequence at least 90% identical to the nucleotide sequence set forth as nucleotides 1-28677 and 29812-34402 of SEQ ID NO: 3.3. The isolated recombinant nucleic acid molecule of claim 2 , comprising the nucleic acid sequence set forth as SEQ ID NO: 1 claim 2 , SEQ ID NO: 2 claim 2 , SEQ ID NO: 3 or a degenerate variant thereof.4. A cDNA comprising a nucleic acid sequence at least 90% identical to an open reading frame of SEQ ID NO: 1 claim 2 , SEQ ID NO: 2 or SEQ ID NO: 3.5. The cDNA of claim 4 , comprising an open reading frame of the nucleic acid sequence set forth as SEQ ID NO: 1 claim 4 , SEQ ID NO: 2 or SEQ ID NO: 3.6. An isolated polypeptide encoded by the nucleic acid sequence of .7. The isolated polypeptide of claim 6 , comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth as one of SEQ ...

REARRANGED TT VIRUS MOLECULES FOR USE IN DIAGNOSIS, PREVENTION AND TREATMENT OF CANCER AND AUTOIMMUNITY

The present invention relates to rearranged molecules of (a) a specific TT virus sequence and (b) a nucleotide sequence encoding a polypeptide showing homology to mammalian proteins associated with cancer and autoimmune diseases that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity. 1. A rearranged TT virus polynucleic acid comprising{'figref': {'@idref': 'DRAWINGS', 'FIG. 6'}, '(a) a nucleotide sequence shown in ;'}(b) a nucleotide sequence which shows at least 70% identity to a nucleotide sequence of (a) and is capable of replicating autonomously and/or inducing autonomous replication;(c) a fragment of a nucleotide sequence of (a) or (b) which is capable of replicating autonomously;(d) a nucleotide sequence which is the complement of the nucleotide sequence of (a), (b), or (c); or(e) a nucleotide sequence which is redundant as a result of the degeneracy of the genetic code compared to any of the above-given nucleotide sequences.2. The rearranged TT virus polynucleic acid of consisting of{'figref': {'@idref': 'DRAWINGS', 'FIG. 6'}, '(a) a nucleotide sequence shown in ;'}(b) a nucleotide sequence which shows at least 70% identity to a nucleotide sequence of (a) and is capable of replicating autonomously and/or inducing autonomous replication;(c) a fragment of a nucleotide sequence of (a) or (b) which is capable of replicating autonomously;(d) a nucleotide sequence which is the complement of the nucleotide sequence of (a), (b), or (c); or(e) a nucleotide sequence which is redundant as a result of the degeneracy of the genetic code compared to any of the above-given nucleotide sequences.3. The rearranged TT virus polynucleic acid of claim 1 , wherein said nucleotide sequence of (a) claim 1 , (b) claim 1 , (c) claim 1 , (d) or (e) is linked to a polynucleic acid encoding a polypeptide containing a signature motif of a mammalian protein or allergen being associated with cancer or an ...

METHODS AND COMPOSITIONS FOR ANTIBODY-EVADING VIRUS VECTORS

The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo. 2. The cell of claim 1 , wherein the cell is ex vivo or in vitro.3. The cell of claim 1 , wherein the cell is in vivo.4. The cell of claim 1 , wherein the nucleic acid encodes a heterologous polypeptide.5. The cell of claim 1 , wherein the nucleic acid encodes a heterologous RNA.6. The cell of claim 4 , wherein the nucleic acid comprises one or more regulatory sequences which direct expression of the heterologous polypeptide in the cell.7. The cell of claim 6 , wherein the one or more regulatory sequences are inducible promoter or enhancer elements.8. The cell of claim 6 , wherein the one or more regulatory sequences are tissue-specific regulatory sequences.9. The cell of claim 6 , wherein the one or more regulatory sequences are operably linked to the nucleic acid encoding the heterologous polypeptide.10. The cell of claim 1 , wherein the capsid protein comprises a substitution which confers heparin and/or heparan sulfate binding.11. The cell of claim 10 , wherein a heparin binding domain is substituted into the capsid protein.12. The cell of claim 11 , wherein the heparin binding domain comprises the amino acid sequence BXXB (SEQ ID NO:163) claim 11 , wherein B is a basic residue and X is a neutral and/or hydrophobic amino acid residue.13. The cell of claim 1 , wherein the capsid protein comprises an RGD peptide sequence.14. A method of producing a recombinant AAV vector claim 1 , the method comprising maintaining the cell of under conditions wherein the nucleic acid is packaged within an AAV capsid comprising the capsid protein to produce the recombinant AAV vector.15. The method of claim 14 , wherein the method comprises lysing the cell and collecting the ...

HUMAN ORTHOPOXVIRUS ANTIBODIES AND METHODS OF USE THEREFOR

The present disclosure is directed to antibodies binding to and neutralizing Poxvirus and methods for use thereof. 1. A method of detecting an orthopoxvirus infection in a subject comprising:(a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively; and(b) detecting orthopoxvirus in said sample by binding of said antibody or antibody fragment to a orthopoxvirus antigen in said sample.212-. (canceled)13. A method of treating a subject infected with orthopoxvirus , or reducing the likelihood of infection of a subject at risk of contracting orthopoxvirus , comprising delivering to said subject an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4 , respectively.14. The method of claim 13 , the antibody or antibody fragment is encoded by clone-paired light and heavy chain variable sequences as set forth in Table 1.15. The method of claim 13 , the antibody or antibody fragment is encoded by clone-paired light and heavy chain variable sequences having 95% identify to as set forth in Table 1.16. The method of claim 13 , wherein said antibody or antibody fragment is encoded by light and heavy chain variable sequences having 70% claim 13 , 80% claim 13 , or 90% identity to clone-paired sequences from Table 1.17. The method of claim 13 , wherein said antibody or antibody fragment comprises light and heavy chain variable sequences according to clone-paired sequences from Table 2.18. The method of claim 13 , wherein said antibody or antibody fragment comprises light and heavy chain variable sequences having 70% claim 13 , 80% or 90% identity to clone-paired sequences from Table 2.19. The method of claim 13 , encoded by light and heavy chain variable sequences having 95% identity to clone-paired sequences from Table 2.20. The method of claim 13 , wherein the antibody fragment is a recombinant ScFv (single chain ...

Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases

Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.

Mosaic chimeric viral vaccine particle

The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response. In other embodiments, vectors that recruit and activate specific antigen-presenting cells may further enhance the efficacy of those immune responses.

CANINE CIRCOVIRUS SEQUENCES AND USES THEREOF

The invention is directed to a isolated a canine circoviruses associated with canine respiratory and gastrointestinal disease, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to antibodies against antigens from canine circoviruses. The invention also relates to iRNAs which target nucleic acid sequences of the canine circovirus. The invention is related to methods for detecting the presence or absence of canine circoviruses in an animal. The invention is also related to immunogenic compositions for inducing an immune response against canine circoviruses in an animal. 1. An isolated nucleic acid having the sequence of SEQ ID NO: 1.2. An isolated nucleic acid having at least about 60% sequence identity to SEQ ID NO: 1.3. An isolated nucleic acid which comprises at least 10 consecutive nucleotides of SEQ ID NO: 1.4. An isolated nucleic acid which comprises at least 10 consecutive nucleotides of a sequence having at least about 60% identity to SEQ ID NO: 1.5. An isolated nucleic acid which comprises consecutive nucleotides having a sequence complementary to the nucleic acid of or .6. An isolated polypeptide having the sequence of any of SEQ ID NOs: 2-4.7. An isolated polypeptide having at least about 80% sequence identity to any of SEQ ID NO: 2-4.8. An isolated polypeptide comprising at least 8 consecutive amino acids of any of SEQ ID NOs 2-4.9. An isolated polypeptide comprising at least 8 amino acids having at least about 80% identity to the sequence of any of SEQ ID NOs 2-4.109. An isolated nucleic acid encoding the polypeptide of any of -.119. An isolated antibody that specifically binds to a polypeptide of any of -.12. An immunogenic composition comprising at least about 24 consecutive nucleotides from the nucleic acid of or .13. An immunogenic composition comprising at least about 8 consecutive amino acids of or .14. A method of inducing an immune response in an animal claims 6 , the method comprising administering the ...

CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES

The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell. 1. A method of inhibiting viral infection of an animal host cell , the method comprising administering to the host cell an antiviral-effective amount of an active agent selected from the group consisting of a purified , integrin-binding gB disintegin-like peptide and a purified antibody that binds specifically to an integrin-binding , gB disintegrin-like peptide.2. The method of claim 1 , wherein the active agent comprises a purified claim 1 , integrin-binding gB disintegrin-like peptide.3. The method of claim 2 , wherein the purified claim 2 , integrin-binding gB disintegrin-like peptide comprises an amino acid consensus sequence RXDLXXFXC (SEQ. ID. NOS: 1-4) or an amino acid sequence at least 80% homologous thereto.4. The method of claim 2 , wherein the purified claim 2 , integrin-binding gB disintegrin-like peptide comprises an amino acid sequence RVCSMAQGTDLIRFERNIVC (SEQ. ID. NO: 5) or an amino acid sequence at least 80% homologous thereto.5. The method of claim 2 , wherein the active agent is administered via a route selected from the group consisting of parenterally claim 2 , orally claim 2 , subcutaneously claim 2 , and topically.6. The method of claim 1 , wherein the active agent comprises a purified antibody that binds specifically to an integrin-binding claim 1 , gB disintegrin-like peptide.7. The method of claim 6 , wherein the purified antibody binds selectively to an ...

Mosaic Chimeric Viral Vaccine Particle

The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response. In other embodiments, vectors that recruit and activate specific antigen-presenting cells may further enhance the efficacy of those immune responses. 1. A modified live vaccine particle coated with a bi-specific diabody , wherein said bi-specific diabody comprises a virus-masking motif having affinity to at least one of a plurality of antigenic sites on said vaccine particle , said plurality of antigenic sites derived from two or more of the BVDV 1 or BVDV 2 proteins selected from the group consisting of N , capsid , Ems , E1 , E2 , NS2 and NS3.2. The modified live vaccine of claim 1 , wherein said at least one of said bi-specific diabody further comprises a cell surface antigen binding moiety fused in-frame with said plurality of antigenic sites.3. The modified viral vaccine of claim 2 , wherein said cell surface antigen binding moiety is a dendritic cell surface antigen binding moiety.4. The modified live vaccine particle of claim 1 , further comprising a single chain antibody having specific affinity for CD205.5. The modified live vaccine particle of claim 1 , wherein said particle is a modified live vectored vaccine.6. The modified live vaccine particle of claim 1 , wherein said bi-specific diabody comprises a CD205-BVDV 1 & 2-specific antibody conjugate.7. The modified live vaccine of claim 3 , wherein said dendritic cell surface antigen binding moiety is a bovine CD205 antigen receptor binding moiety.8. The modifed live vaccine of claim 2 , wherein said viral antigen binding moiety binds to at least one of said plurality of antigenic sites.9. The modified live vaccine of claim 1 , wherein said at least one of ...

VACCINIA VIRUS H3L AND B5R SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF MAKING AND USING SAME

The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof. 1. An isolated or purified antibody or subsequence thereof that binds to poxvirus H3L envelope protein , wherein the antibody or subsequence comprises a sequence greater than 95% identity to heavy chain variable region sequence set forth as SEQ ID NO:14 , and a sequence identical to light chain variable region sequence set forth as SEQ ID NO:16.2. An isolated or purified antibody or subsequence that binds to poxvirus H3L envelope protein , wherein the antibody or subsequence comprises heavy chain variable region sequence CDRs identical to the heavy chain variable region sequence CDRs of the antibody produced by the hybridoma cell line #58 having a deposit designation of PTA-10767 and deposited on Apr. 6 , 2010 (ATCC 10801 University Blvd. , Manassas , Va. 20110-2209).3. An isolated or purified antibody or subsequence thereof that binds to poxvirus H3L envelope protein , wherein the antibody or subsequence comprises a heavy chain variable region sequence identical to the heavy chain variable region sequence of the antibody produced by the hybridoma cell line #58 having a deposit designation of PTA-10767 and deposited on Apr. 6 , 2010 (ATCC University Blvd. , Manassas , Va. 20110-2209).4. The antibody or subsequence thereof of claim 2 , wherein the antibody is produced by the hybridoma cell line #58 having a deposit designation of PTA-10767 and deposited on Apr. 6 claim 2 , 2010 (ATCC 10801 University Blvd. claim 2 , Manassas claim 2 , Va. 20110-2209).5. The antibody or subsequence of claim 1 , wherein said antibody or subsequence thereof inhibits or competes for binding of the antibody produced by the hybridoma cell line #58 having a deposit designation of PTA-10767 and deposited on Apr. 6 claim 1 , 2010 (ATCC 10801 University Blvd. ...

METHODS OF AAV THERAPY

This disclosure provides methods for identifying a subject suitable for an adeno associated vims (AAV) therapy. In some embodiments, the method comprises measuring a titer of an antibody or antigen-binding portion thereof that specifically binds to an AAV (“anti-AAV antibody”) in a biological sample obtained from the subject using an enzyme-linked immunosorbent assay (ELISA). 1. A method of identifying a subject suitable for an adeno associated virus (AAV) therapy , comprising measuring a titer of an antibody or antigen-binding portion thereof that specifically binds to an AAV (“anti-AAV antibody”) in a biological sample obtained from the subject using an enzyme-linked immunosorbent assay (ELISA).2. The method of claim 1 , further comprising administering an AAV therapy to a subject identified as having a low titer of the anti-AAV antibody.3. A method of treating a disease in a subject claim 1 , comprising administering to the subject an AAV therapy claim 1 , wherein the subject is identified as having a low titer of an anti-AAV antibody as measured using a biological sample obtained from the subject in an ELISA.4. A method of treating a disease in a subject claim 1 , comprising (1) measuring the titer of an anti-AAV antibody in a biological sample obtained from the subject in an ELISA claim 1 , wherein the subject is identified as having a low titer of an anti-AAV antibody and (2) administering to the subject identified as having a low titer of an anti-AAV antibody an AAV therapy.5. A method of treating a disease in a subject claim 1 , comprising (1) obtaining a biological sample from the subject claim 1 , (2) measuring the titer of an anti-AAV antibody in the biological sample in an ELISA claim 1 , wherein the subject is identified as having a low titer of an anti-AAV antibody claim 1 , and (3) administering to the subject identified as having a low titer of an anti-AAV antibody an AAV therapy.6. The method of any one of to claim 1 , wherein the disease is in the ...

MONOCLONAL ANTIBODIES AGAINST ORTHOPOXVIRUSES

The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. 1. A substantially pure polypeptide comprising a fully human or humanized chimpanzee monoclonal antibody that binds B5 antigen , wherein said monoclonal antibody comprises a heavy chain CDR1 region having the amino acid sequence of SEQ ID NO:19 , a heavy chain CDR2 region having the amino acid sequence of SEQ ID NO:21 , a heavy chain CDR3 region having the amino acid sequence of SEQ ID NO:23 , a light chain CDR1 region having the amino acid sequence of SEQ ID NO:27 , a light chain CDR2 region having the amino acid sequence of SEQ ID NO:29 and a light chain CDR3 region having the amino acid sequence of SEQ ID NO:31.24-. (canceled)5. The substantially pure polypeptide of wherein said antibody comprises a Fd fragment.6. The substantially pure polypeptide of wherein said antibody comprises a Fab fragment.722-. (canceled)23. A pharmaceutical preparation comprising the monoclonal antibody of .24. A diagnostic preparation comprising the monoclonal antibody of .25. A method for inhibiting Orthopoxvirus infection comprising:{'claim-ref': {'@idref': 'CLM-00023', 'claim 23'}, 'administering to a patient an effective amount of the pharmaceutical preparation of to inhibit said Orthopoxvirus infection.'}26. (canceled)27. A method for the diagnosis of Orthopoxvirus infection comprising:{'claim-ref': {'@idref': 'CLM-00024', 'claim 24'}, 'obtaining the diagnostic preparation of ;'} ...

Fusion Proteins Comprising a Cell Surface Marker Specific VHH

The present invention relates to fusion proteins comprising a cell surface marker specific VHH. In particular, the invention relates to bispecific VHH adaptor proteins, i.e. fusion proteins comprising an adeno-associated virus (AAV) specific VHH linked to a cell surface marker specific VHH. Moreover, the invention relates to a recombinant AAV which comprises a fusion protein in which a cell surface marker specific VHH is integrated into a capsid protein of the AAV. Also nucleotide sequences encoding such fusion proteins, vectors are contemplated. The invention moreover refers to uses of the fusion proteins and nucleic sequences for gene therapy. 1. Fusion protein comprising a cell surface marker specific VHH.2. Fusion protein according to further comprising an adeno-associated virus (AAV) specific VHH.3. The fusion protein according to any one of the preceding claims claim 1 , wherein the serotype of the AAV is selected from the group consisting of AAV1 claim 1 , AAV2 claim 1 , AAV3 claim 1 , AAV4 claim 1 , AAV5 claim 1 , AAV6 claim 1 , AAV7 claim 1 , AAV8 claim 1 , AAV9 claim 1 , AAV10 claim 1 , AAV11 claim 1 , AAV12 claim 1 , AAVrh10 or variants thereof or a combination thereof.4. The fusion protein according to any one of the preceding claims claim 1 , wherein the serotype of the AAV is AAV1 and/or AAV2 or variants thereof.5. The fusion protein according to claim 4 , wherein the serotype of the AAV is AAV1.6. The fusion protein according to claim 5 , wherein the sequence of the adeno-associated virus (AAV) specific VHH is selected from the group consisting of SEQ ID NO: 20 to 24 or sequences having at least 80% identity thereto.7. The fusion protein according to claim 4 , wherein the serotype of the AAV is AAV1 or AAV2.8. The fusion protein according to claim 7 , wherein the sequence of the adeno-associated virus (AAV) specific VHH is selected from the group consisting of SEQ ID NO: 25 to 27 or sequences having at least 80% identity thereto.9. The fusion protein ...

Parvovirus Antibodies for Veterinary Use

Provided are various embodiments relating to parvovirus antibodies, including caninized, felinized, and chimeric antibodies, that bind to canine and/or feline parvovirus, for example, having improved expression characteristics. In various embodiments, the parvovirus antibodies have ADCC, ADCP, and/or CDC effector functions. In various embodiments, such monoclonal parvovirus antibodies can be used in methods to prevent and/or treat parvoviral infection in subjects, such as dogs and cats. For example, the parvovirus antibodies provided may be used to provide passive immunity against infection with a canine or feline parvovirus. 1. An isolated antibody that binds to canine parvovirus and/or feline parvovirus , wherein the antibody comprises:(a) (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5, (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6, and (iv) an HC-FR1 sequence of SEQ ID NO: 7 or SEQ ID NO: 8; or(b) (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 42, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 43, (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 44, and (iv) an HC-FR1 sequence of SEQ ID NO: 45 or SEQ ID NO: 46.2. An isolated antibody that binds to canine parvovirus and/or feline parvovirus , wherein the antibody comprises:(a) (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 13, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 14, (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 15, and (iv) an LC-FR1 sequence of SEQ ID NO: 16; or(b) (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 52, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 53, (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 54, and (iv) an LC-FR1 sequence of SEQ ID NO: 55 or SEQ ID NO: 56.3. The isolated antibody of claim 1 , wherein the antibody of (a) comprises an HC-FR4 ...

TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS

The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject. 1. A method for the treatment of ocular neovascularization in an eye of a human subject suffering from ocular neovascularization , said eye of the human subject having previously received a first intravitreal injection of an anti-Vascular Endothelial Growth Factor (VEGF) agent in an amount such that the anti-VEGF agent is present in the eye of the subject at a concentration sufficient to prevent progression of the neovascularization at the time of application of the method , the method comprising:{'sup': 6', '15, 'administering to the eye of the human subject a single dose of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant virus comprising a nucleic acid sequence encoding an anti-VEGF protein, wherein the single dose comprises at least 1×10and at most 1×10vector genomes of the recombinant virus, and is sufficient to cause elevated levels of said anti-VEGF protein in the eye of said human subject when measured at least one year after the administration of the pharmaceutical composition;'}wherein the eye of the subject does not require rescue treatment with an anti-VEGF agent to arrest or reverse progression of the ocular neovascularization during the period between about 180 days and about one year following the administration of the pharmaceutical composition.2. The method of wherein the recombinant virus is a recombinant adeno-associated virus (rAAV).3. The method of claim 2 , wherein the rAAV is selected from the group consisting of: AAV1 claim 2 , AAV2 claim 2 , AAV2.5 AAV3 claim 2 , AAV4 claim 2 , AAV5 claim 2 , AAV6 claim 2 , AAV7 claim 2 ...

Rift Valley Fever Virus Glycoproteins, GN and GC, and their Use

The present invention describes subunit vaccines containing Gn and Gc glycoproteins of the Rift Valley Fever Virus, including nucleic acids encoding such glycoproteins, host cells, vectors, and immunoreagents generated with the glycoproteins, methods of vaccination, methods of diagnosis, and kits. 1. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:1 , wherein said isolated nucleic acid molecule encodes an polypeptide or protein consisting essentially of an amino acid sequence as set forth in SEQ ID NO: 4 or SEQ ID NO:6.2. The isolated nucleic acid molecule of claim 1 , wherein said encoded polypeptide or protein induces neutralizing antibodies against Rift Valley Fever Virus (RVFV) in a subject at primary dose.3. The isolated nucleic acid molecule of claim 2 , wherein said molecule encodes a functional fragment of said encoded polypeptide or protein.4. The isolated nucleic acid molecule of claim 1 , wherein said nucleic acid molecule is selected from the group consisting of: SEQ ID NO:3 claim 1 , SEQ ID NO:5 claim 1 , functional fragments thereof claim 1 , and sequences having at least 90% homology to SEQ ID NO:3 or SEQ ID NO:5 claim 1 , wherein said nucleic acid molecule encodes a polypeptide or protein which induces neutralizing antibodies against Rift Valley Fever Virus in a subject at primary dose.5. The isolated nucleic acid molecule of claim 1 , wherein said nucleic acid molecule further comprises one or more regulatory nucleic acid sequences selected from the group consisting of Kozak sequences claim 1 , promoter sequences claim 1 , transcriptional enhancers claim 1 , polyadenylation sites claim 1 , TATA boxes claim 1 , initiators claim 1 , CpG Islands claim 1 , promoter proximal elements claim 1 , operons claim 1 , and combinations thereof.6. A host cell comprising the nucleic acid molecule of claim 1 , wherein said host cell is selected from the group consisting of a mammalian cell claim 1 , a bacterial cell ...

Hexon protein hypervariable region gene sequence of adenovirus and its application

The invention provides a Gene sequence which can encode and express adenovirus hexon protein in vitro, and is represented as SEQ ID NO: 3. Also invented a protein which was translated and expressed by the gene sequence according to the invention, and the invention also relates to the use of the protein as an antigen to immunize rabbits to obtain a polyclonal antibody. The antibody mentioned above can detect adenovirus with high sensitivity and specificity. 1. A gene sequence of adenovirus hexon as shown as SEQ ID NO: 3 which can encode and express adenovirus hexon protein in vitro.2. The sequence according to claim 1 , which was obtained by amplifying of Hexon-HVR full-length gene sequence with NCBI serial number of AC_000008.1 claim 1 , and the sequence was located at 19250 bp-20188 bp.3. The sequence according to claim 2 , the described amplification primers are represented as SEQ ID NO: 1 and SEQ ID NO: 2.4. An adenovirus hexon protein claim 2 , which was expressed and translated in vitro by the gene sequence according to SEQ ID NO: 3.5E. coli.. The protein according to claim 4 , which was translated and expressed in6. The protein according to claim 5 , after the protein was expressed claim 5 , it was purified by the following steps:i) the inclusion body which have expressed were collected by centrifuging at 8000 rpm for 10 min;ii) the obtained inclusion body was resuspended with 15 ml inclusion body washing solution, and slowly stirred at 37° C. for 30 min, then centrifuged at 4000 rpm for 30 min, and rewashing again after collecting the inclusion body pellet;{'sub': '2', 'iii) after centrifugation and washing twice with washing solution, the inclusion body was resuspended with 15 ml inclusion body purification solution A, slowly stirred at 37° C. for 30 min, then centrifuged at 8000 rpm for 10 min, and collecting the supernatant; iv) the supernatant was added to a well-balanced nickel column (nickel column was balanced by 3 times of column volumes of ddHO and 3 ...

INTERFERON ANTAGONISTS, ANTIBODIES THERETO, AND ASSOCIATED METHODS OF USE

Described are compositions and methods useful for modulating the immune system of a subject. Also included are diagnostic methods for monitoring an immunologic condition. In particular the invention relates to antagonists of interferon proteins and associated methods of use as well as methods to develop neutralizing antibodies against IFN antagonists to treat viral infections. 1. A therapeutic composition comprising: a therapeutically effective amount of an isolated polypeptide having IFN I and IFN III antagonist activity; and at least one of a pharmaceutically acceptable carrier , excipient , or adjuvant.2. The therapeutic of claim 1 , wherein the polypeptide has at least 30% sequence identity to SEQ ID NO. 1 or portion thereof.3. The therapeutic of claim 1 , wherein the polypeptide is a fusion protein comprising at least one other polypeptide portion located at either of the amino terminus claim 1 , the carboxy terminus claim 1 , or both claim 1 , and wherein the polypeptide portions are disposed in a single claim 1 , contiguous polypeptide chain.4. The therapeutic of claim 3 , wherein the fusion protein comprises a polypeptide portion comprising SEQ ID NO. 1 or a portion thereof and a second polypeptide portion comprising SEQ ID NO. 5 or portion thereof.5. An isolated nucleic acid molecule comprising a first polynucleotide component having at least 30% sequence homology to SEQ ID. NO. 2 or portion thereof claim 3 , and at least one additional polynucleotide component contiguous with the first claim 3 , wherein the additional polynucleotide component is disposed at the 5′ end or the 3′ end of the nucleic acid claim 3 , and wherein both are contained within a single open reading frame.6. A fusion protein encoded by the isolated nucleic acid of .7. The isolated nucleic acid of claim 6 , wherein the at least one other polynucleotide portion encodes at least one member selected from group consisting of a fluorescent protein claim 6 , a FLAG tag claim 6 , an HA tag ...

Infectivity-enhanced conditionally-replicative adenovirus and uses thereof

A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.

Tropism-Modified Recombinant Viral Vectors and Uses Thereof for the Targeted Introduction of Genetic Material into Human Cells

Provided herein are compositions and methods for retargeting recombinant viral capsid proteins/capsids/vectors, e.g., in vivo, with a multispecific binding molecule, such as a bispecific antibody, that specifically binds a heterologous epitope displayed by the capsid protein and a protein expressed on the cell of interest for the targeted delivery of a nucleotide of interest. 1. A recombinant viral capsid protein comprising an epitope that is heterologous to the capsid protein ,wherein the heterologous epitope or portion thereof specifically binds an antibody paratope, andwherein the viral capsid protein forms recombinant viral capsid with reduced or abolished natural tropism.23.-. (canceled)4. The recombinant viral capsid protein of claim 1 , wherein the viral capsid protein is derived from adeno-associated virus (AAV) capsid gene claim 1 , optionally wherein the heterologous epitope is inserted into a position selected from the group consisting of I587 of AAV2 claim 1 , I585 of AAV6 claim 1 , I590 of AAV8 claim 1 , I453 of AAV9 claim 1 , I589 of AAV9 claim 1 , and any corresponding amino acids of an AAV serotype that infects primates claim 1 , optionally wherein the AAV serotype that infects primates is selected from the group consisting of AAV1 claim 1 , AAV2 claim 1 , AAV3 claim 1 , AAV4 claim 1 , AAV5 claim 1 , AAV6 claim 1 , AAV7 claim 1 , AAV8 claim 1 , and AAV9.5. The recombinant viral capsid protein of claim 4 , wherein the adeno-associated virus is AAV2 claim 4 , AAV6 claim 4 , AAV8 claim 4 , or AAV9.68.-. (canceled)9. The recombinant viral capsid protein of claim 1 , wherein(i) the viral capsid protein is a genetically modified AAV2 VP1 capsid protein and the epitope is inserted after and/or replaces an amino acid at position I453 or I587;(ii) the viral capsid protein is a genetically modified AAV6 VP1 capsid protein and the epitope is inserted after and/or replaces an amino acid at position I585;(iii) the viral capsid is a genetically modified AAV8 VP1 ...

INFECTIOUS CLONES OF TORQUE TENO VIRUS

The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen. 1. An isolated polynucleotide sequence that comprises a polynucleotide selected from the group consisting of:{'sub': '1', '(a) the DNA of genotype 2 sequence TTV13 (SEQ ID NO: 1); the DNA genotype 2 sequence TTV10 (SEQ ID NO: 2); or a fragment thereof than encodes the TTV capsid protein or a fragment of said protein;'}{'sub': '2', '(a) the DNA of a genotype 1 sequence selected from the group consisting of ttvg1-7 (SEQ ID NO: 4), ttvGT1-17 (SEQ ID NO: 5), ttvGT1-21 (SEQ ID NO: 6), ttvgt1-27 (SEQ ID NO: 3), and ttvgt1-178 (SEQ ID NO: 7) or a fragment thereof than encodes the TTV capsid protein or a fragment of said protein;'}(b) the complement of any sequence in (a);{'sub': '4', '(c) a polynucleotide that hybridizes with a sequence of (a) or (b) under stringent conditions defined as hybriding to filter bound DNA in 0.5M NaHPO, 7% SDS, 1 mM EDTA at 65° C., and washing in 0.1×SSC/0.1% SDS at 68° C.;'}(d) a polynucleotide that is at least 70% identical to the polynucleotide of (a) or (b);(e) a polynucleotide that is at least 80% identical to the polynucleotide of (a) or (b);(f) a polynucleotide that is at least 90% identical to the polynucleotide of (a) or (b); and(g) a polynucleotide that is at least 95% identical to the polynucleotide of or (b).2 ...

PORCINE CIRCOVIRUS TYPE 3 IMMUNOGENIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME

A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions. 1. A composition comprising:at least one porcine circovirus type 3 protein selected from the group consisting of ORF1, ORF2, and ORF3; anda veterinary-acceptable carrier selected from the group consisting of a solvent, a dispersion media, a coating, a stabilizing agent, a diluent, a preservative, an antimicrobial agent, an antifungal agent, an isotonic agent, an adsorption delaying agent, or any combination thereof.2. The composition of claim 1 , wherein said protein is encoded by a nucleotide sequence having at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NO. 3 claim 1 , SEQ ID NO. 5 claim 1 , SEQ ID NO. 7 claim 1 , or wherein said protein has at least 90% sequence homology with a sequence selected from the group consisting of SEQ ID NO. 4 claim 1 , SEQ ID NO. 6 claim 1 , SEQ ID NO. 8 claim 1 , or any combination thereof.3. The composition of claim 1 , further comprising an immune stimulant.4Actinobacillus pleuropneumoniaBordetella bronchiseptica; BrachyspiraB. hyodyentheriae; B. piosicoli, Brucella suisClostridiumCl. difficile, Cl. perfringensCl. novyi, Cl. septicum, Cl. tetaniEperythrozoonosis suis; Erysipelothrix rhsiopathiae; Escherichia coli; Haemophilus parasuisLawsonia intracellularis; LeptospiraLeptospira australis; Leptospira canicola; Leptospira grippotyphosa; Leptospira icterohaemorrhagicaeLeptospira interrogans; Leptospira pomona; Leptospira tarassovi; MycobacteriumM. avium; M. intracellulareM. bovis; Mycoplasma hyopneumoniaeM. hyoPasteurella multocidaSalmonellaS. thyhimuriumS. choleraesuis; ...

Composition and Methods for Treating Acute Diarrhea and Enteric

The composition may be used therapeutically or prophylactically and is directed toward a cluster of diarrhea-causing pathogens which cause illness or death in animals, including dogs and cats. It is prepared from a powdered egg preparation and powdered protein matrix, such as bovine colostrum. The eggs are collected from hens which have been immunized with the relevant pathogens or toxins. When the matrix includes colostrum, the powdered colostrum is derived from non-hyperimmune cattle. The vaccination strategy includes the use of antibody cross-reactivity between toxins or pathogens which cause diarrhea. For some diseases, including canine parvo, the clinical improvement using this therapeutic exceeds the standard of care. Instead of a pharmaceutical product, this composition is an orally administered food product with the same safety profile as eggs and milk.

METHOD FOR TREATING SOLUTION CONTAMINATED WITH PORCINE CIRCOVIRUSES

The present invention provides a method for treating a solution contaminated with porcine circovirus, comprising the steps of: adjusting a pH of a solution contaminated with porcine circovirus to range from 3.0 to 7.0; and treating the pH-adjusted solution with a filtration membrane having an LRV for bacteriophage PP7 of 4 or more. 1. A method for treating a solution contaminated with porcine circovirus , comprising:adjusting a pH of a solution contaminated with porcine circovirus to range from 3.0 to 7.0; andtreating the pH-adjusted solution with a filtration membrane having an LRV for bacteriophage PP7 of 4 or more.2. The method for treating a solution contaminated with porcine circovirus according to claim 1 , wherein the pH-adjusted solution contains not more than 0.50 M glycine.3. The method for treating a solution contaminated with porcine circovirus according to claim 2 , wherein the solution contains 0.010 to 0.40 M glycine.4. The method for treating a solution contaminated with porcine circovirus according to claim 2 , wherein the solution contains 0.20 to 0.35 M glycine.5. The method for treating a solution contaminated with porcine circovirus according to claim 1 , wherein the solution contaminated with porcine circovirus contains not more than 5.0 w/v % of a protein.6. The method for treating a solution contaminated with porcine circovirus according to claim 5 , wherein when the protein concentration in the solution contaminated with porcine circovirus is less than 0.10 w/v % claim 5 , the pH of the solution contaminated with porcine circovirus is adjusted to range from 3.0 to 6.0.7. The method for treating a solution contaminated with porcine circovirus according to claim 5 , wherein when the protein concentration of the solution contaminated with porcine circovirus ranges from 0.10 to 1.5 w/v % claim 5 , the pH of the solution contaminated with porcine circovirus is adjusted to range from 3.8 to 7.0.8. The method for treating a solution contaminated ...

APHERESIS METHODS AND USES

Provided are methods of treating a subject in need of treatment for a disease caused by a loss of function or activity of a protein. Also provided are methods of treating a subject in need of treatment for a disease caused by a gain of function, activity or expression, of a protein. 1. A method of treating a subject in need of treatment for a disease caused by a loss of function or activity of a protein comprising: (a) removing , reducing , depleting , inhibiting , inactivating or capturing AAV binding antibodies from a blood product obtained from the subject by a process comprising apheresis; and (b) administering an amount of a recombinant adeno-associated virus (rAAV) vector comprising a heterologous polynucleotide that encodes a protein or peptide that provides or supplements a function or activity of the protein.2. A method of treating a subject in need of treatment for a disease caused by a gain of function , activity or expression , of a protein comprising: (a) removing , reducing , depleting , inhibiting , inactivating or capturing AAV binding antibodies from a blood product obtained from the subject by a process comprising apheresis; and (b) administering an amount of a recombinant adeno-associated virus (rAAV) vector comprising a heterologous polynucleotide that is transcribed into a nucleic acid that inhibits , decreases or reduces expression of the gain of function , activity or expression of the protein.3. The method of or , wherein the apheresis process comprises an AAV binding antibody affinity matrix attached to or immobilized on a substrate.4. The method of claim 3 , wherein the AAV binding antibody affinity matrix comprises an AAV capsid or AAV capsid fragment attached to or immobilized on a substrate that binds to the AAV binding antibodies in the blood product.5. The method of any of - claim 3 , wherein the AAV binding antibody affinity matrix immobilized on a substrate is disposed within a column claim 3 , apparatus claim 3 , chamber claim 3 , ...

ENGINEERED HUMAN ANTI-AAV ANTIBODIES AND USES THEREOF

A method for generating engineered human anti-AAV antibodies is described. Also described are compositions, panels and arrays containing these antibodies and uses thereof. 2. The antibody according to claim 1 , wherein the heterologous sequence is a heavy chain and/or light chain constant region.3. The antibody according to claim 1 , wherein the heterologous sequence is a framework region into which the fragment comprising the one or more CDRs is inserted.4. A synthetic nucleic acid sequence encoding an immunoglobulin comprising a kappa light chain variable region according to claim 1 , a lambda light chain according to claim 1 , or a fragment thereof.5. A synthetic nucleic acid sequence encoding an immunoglobulin comprising a heavy chain variable region according to (a) and a light chain variable region of (b) or (c) according to .6. A panel of human anti-AAV antibodies claim 1 , wherein said panel comprises two or more anti-AAV antibodies according to any one of to .7. The panel according to claim 6 , which comprises 3 to 25 anti-AAV antibodies directed against a single AAV.8. A solid support comprising one or more of an anti-AAV heavy chain claim 1 , kappa light chain claim 1 , or a lambda light chain of .9. A method of purifying an AAV vector comprising contacting a suspension comprising a selected AAV with the solid support of .10. A method of generating human anti-AAV antibodies which comprises:(a) sorting memory B cells from a sample comprising human plasma;(b) culturing the memory B cells and screening supernatant from the cell culture for anti-AAV activity and/or binding to AAV;(c) amplifying immunoglobulins from the cell culture supernatant selected from one or more of a heavy chain and/or a light chain, or a fragment thereof using RT-PCR;(d) cloning sequences encoding the immunoglobulins produced from the amplified immunoglobulins of (c); and(e) sequencing the sequences obtained from the clones and generating an immunoglobulin consensus sequence.11. The ...

HUMAN MONOCLONAL ANTIBODY AGAINST THE VP1 PROTEIN OF JC VIRUS

A human neutralizing monoclonal antibody is directed against the VP1 protein of JC virus. The JC virus is responsible for progressive multifocal leukoencephalopathy (PML). The antibody is used in a therapeutic or prophylactic treatment of a JCV infection or of a disease associated with a JCV infection, such as progressive multifocal leukoencephalopathy (PML). The antibody is also used in the diagnosis of JCV infections or of diseases associated with JCV infections. 1. A monoclonal antibody directed against the VP1 protein of JC virus , wherein the monoclonal antibody is a human antibody and is capable of neutralizing the JC virus.2. The monoclonal antibody according to claim 1 , which is capable of binding to a conformational epitope of the JCV VP1 protein claim 1 , comprising at least one amino acid residue of the primary sequence of the JCV VP1 protein selected from the group consisting of I62 claim 1 , S65 claim 1 , A127 claim 1 , D130 claim 1 , N131 claim 1 , A133 claim 1 , A175 claim 1 , and any combination thereof.3. The monoclonal antibody according to claim 2 , wherein the conformational epitope of the JCV VP1 protein comprises the amino acid residues I62 claim 2 , S65 claim 2 , A127 claim 2 , D130 claim 2 , N131 claim 2 , A133 and A175 of the primary sequence of the JCV VP1 protein.4. The monoclonal antibody according to claim 1 , which is a full-length immunoglobulin or a functional immunoglobulin fragment selected from the group consisting of Fab claim 1 , Fab′ claim 1 , F(ab′) claim 1 , Fv claim 1 , single chain antibodies (scFv) and single domain antibodies.5. The monoclonal antibody according to claim 1 , comprising at least a heavy chain variable region and a light chain variable region claim 1 , wherein the heavy chain variable region has the sequence SEQ ID NO:1 and the light chain variable region has the sequence SEQ ID NO:2 claim 1 , or the heavy chain variable region is encoded by the sequence SEQ ID NO:3 and the light chain variable region is ...

METHOD FOR LARGE SCALE PRODUCTION AND PURIFICATION OF PARVOVIRUS

Described is a reproducible, effective and scalable process for parvovirus production including characterization strategies, preferably production of H-1PV. 1. A method for producing empty inactive or full active parvovirus particles , said method comprising:(a) providing the producer cell line NB-324K;(b) growing the cell line under suitable conditions and infecting the cells at a cell density from 2.0 to 5.0×104 cells/cm2 with the parvovirus at a MOI of 0,5 to 2×10-2 PFU/cells;(c) harvesting the cells 2 to 6 days post-infection and obtaining a cell pellet by centrifugation;(d) subjecting the resuspended cell pellet to a mechanical, physical or chemical cell lysis method for obtaining a parvovirus containing cell lysate;(e) sonicating the cell lysate and subjecting it to DNAse treatment;(f) clarifying the DNAse-treated parvovirus harvest by filtration; and(g1) purifying the parvovirus by two successive density gradient ultracentrifugations, wherein the first gradient is a Iodixanol/PBS step gradient and the second gradient is a Iodixanol/Ringer step gradient or a Iodixanol/Ringer continuous gradient for obtaining full active parvovirus particles in one fraction and empty parvovirus particles in another fraction.2. The method of claim 1 , wherein the cell density of step (b) is from 3.0 to 4.0×104 cells/cm2.3. The method of claim 1 , wherein for step (f) a 0.2-μm filter with prefilter is used.4. The method of claim 1 , wherein the producer cell line NB-324K is characterized by(a) a viability of at least 95%;(b) a passage number below 20; and/or(c) lack of mycoplasma contamination.5. The method of any one of claim 1 , wherein virus production is performed in a collection system.6. The method of claim 5 , wherein the collection system is a 10-layer cell culture chamber.7. The method of claim 1 , wherein the parvovirus is H1-PV.8. The method of further comprising determining the ratio of native parvovirus capsids to non-assembled capsid proteins or denatured capsids.9. ...

MUTATED PARVOVIRUS STRUCTURAL PROTEINS AS VACCINES

The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimerc structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use. 167-. (canceled)68. A method for preventing or treating a disease in a patient in need thereof , the method comprising administering to the patient a medicament comprising at least one parvovirus mutated structural protein , the parvovirus mutated structural protein comprising at least one B-cell epitope heterologous to the parvovirus , wherein the B-cell epitope is located on the surface of the parvovirus mutated structural protein , and wherein the parvovirus mutated structural protein is not used as a vector in gene therapy.69. The method of claim 68 , wherein the B-cell epitope is not identical to a B-cell epitope of a pathogen.70. The method of claim 68 , wherein the parvovirus mutated structural protein comprises at least one B-cell epitope heterologous to the parvovirus which is not identical to a mammalian or pathogen B-cell epitope claim 68 , but is a functional derivative of a mammalian or pathogen B-cell epitope.71. The method of claim 68 , wherein the B-cell epitope is a tolerogen-derived epitope.72. The method of claim 68 , wherein the B-cell epitope is part of a protein selected from the group consisting of a tumor antigen claim 68 , a misfolded protein claim 68 , a serum protein claim 68 , a membrane protein claim 68 , a TNF-family member claim 68 , and an interleukin (IL).73. The method of claim 72 , wherein the B-cell epitope is part of a protein selected from the group consisting of CETP claim 72 , CD20 claim 72 , acetylcholine ...

SALMON GILL POXVIRUS

The present document is directed to a new poxvirus infecting salmon. The present document further discloses the genomic sequence of this double-stranded DNA virus and the use of this sequence information for detection, diagnosis and/or vaccine development for the virus. 1. Piscine poxvirus characterized in that it comprises a nucleic acid sequence according to SEQ ID NO:1 or a nucleic acid sequence having at least 85% identity thereto , and/or a nucleic acid sequence complementary thereto.2. An isolated nucleic acid molecule comprising or consisting of a nucleic acid sequence according to SEQ ID NO:1-9 or a variant thereof having at least 85% identity thereto , and/or a nucleic acid sequence complementary to said nucleic acid sequence or variant thereof.3. A nucleic acid fragment of an isolated nucleic acid molecule according to , said fragment comprising or consisting of at least 5 contiguous nucleic acid bases of a nucleic acid molecule as defined in , wherein said nucleic acid fragment is a nucleic acid primer or nucleic acid probe capable of specifically detecting Piscine poxvirus in a sample.4. (canceled)5. The nucleic acid fragment according to claim 3 , wherein said nucleic acid fragment is a nucleic acid probe comprising or consisting of at least 5 claim 3 , such as about 5-300 claim 3 , 5-100 claim 3 , 10-100 claim 3 , 15-80 claim 3 , 15-50 claim 3 , 18-35 claim 3 , or 15-25 contiguous nucleotides of a nucleic acid sequence according to SEQ ID NO:1-9 claim 3 , such as SEQ ID NO:1-3 claim 3 , or a variant thereof having at least 85% identity thereto claim 3 , or a sequence complementary thereto.6. The nucleic acid fragment according to claim 5 , wherein said nucleic fragment is a nucleic acid probe claim 5 , the nucleic acid sequence of which probe is as defined in any one of SEQ ID NO:4-7.7. The nucleic acid fragment according to claim 3 , wherein said nucleic acid fragment is a primer consisting of at least 5 claim 3 , such as about 5-50 claim 3 , 10-40 ...

INTEGRAL MEMBRANE PROTIEN DISPLAY ON POXVIRUS EXTRACELLULAR ENVELOPED VIRIONS

This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest. 1. An isolated polynucleotide comprising:(a) a first nucleic acid fragment that encodes an integral membrane protein (IMP) or fragment thereof, wherein the IMP or fragment thereof comprises at least one extra-membrane region, at least one transmembrane domain and at least one intra-membrane region, and wherein a portion of the first nucleic acid fragment encoding at least one intra-membrane region is situated at the 5′ or 3′ end of the first nucleic acid fragment; and(b) a second nucleic acid fragment that encodes a poxivirus EEV-specific protein or functional fragment thereof, wherein the second nucleic acid fragment is fused in frame to a portion of the first nucleic acid fragment that encodes an intra-membrane region of the IMP;wherein a poxvirus infected cell comprising the polynucleotide can express an IMP poxvirus EEV-specific protein fusion protein as part of the outer envelope membrane of an extracellular enveloped virion (EEV).2. The polynucleotide of claim 1 , wherein the IMP is a multi-pass membrane protein comprising at least two transmembrane domains.3. The polynucleotide of claim 2 , wherein the IMP has an odd number of transmembrane domains claim 2 , wherein the 5′ end of the first nucleic acid fragment encodes an extra-membrane region claim 2 , wherein the 3′ end of the first nucleic acid fragment encodes an intra-membrane region claim 2 , and wherein the 5′ end of the second polynucleotide is fused to the 3′ end of the first nucleic acid fragment.4. The polynucleotide of claim 3 , wherein the IMP comprises a G-protein coupled receptor (GPCR).5. The polynucleotide of claim 4 , wherein the IMP is the human frizzled-4 protein (FZD4) claim 4 , or a fragment ...

MONOCLONAL ANTIBODIES AGAINST ORTHOPOXVIRUSES

The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. 1. A substantially pure polypeptide comprising a fully human or humanized chimpanzee monoclonal antibody that binds B5 antigen , wherein said monoclonal antibody comprises a heavy chain CDR1 region having the amino acid sequence of SEQ ID NO:19 , a heavy chain CDR2 region having the amino acid sequence of SEQ ID NO:21 , a heavy chain CDR3 region having the amino acid sequence of SEQ ID NO:23 , a light chain CDR1 region having the amino acid sequence of SEQ ID NO:27 , a light chain CDR2 region having the amino acid sequence of SEQ ID NO:29 and a light chain CDR3 region having the amino acid sequence of SEQ ID NO:31.24-. (canceled)5. The substantially pure polypeptide of wherein said antibody comprises a Fd fragment.6. The substantially pure polypeptide of wherein said antibody comprises a Fab fragment.722-. (canceled)23. A pharmaceutical preparation comprising the monoclonal antibody of .24. A diagnostic preparation comprising the monoclonal antibody of .25. A method for inhibiting Orthopoxvirus infection comprising:{'claim-ref': {'@idref': 'CLM-00023', 'claim 23'}, 'administering to a patient an effective amount of the pharmaceutical preparation of to inhibit said Orthopoxvirus infection.'}26. (canceled)27. A method for the diagnosis of Orthopoxvirus infection comprising:{'claim-ref': {'@idref': 'CLM-00024', 'claim 24'}, 'obtaining the diagnostic preparation of ;'} ...

Hexon protein hypervariable region gene sequence of adenovirus and its application

The invention provides a gene sequence which can encode and express adenovirus hexon protein in vitro, and is represented as SEQ ID NO: 3. Also invented a protein which was translated and expressed by the gene sequence according to the invention, and the invention also relates to the use of the protein as an antigen to immunize rabbits to obtain a polyclonal antibody. The antibody mentioned above can detect adenovirus with high sensitivity and specificity. 1. A method for producing an adenovirus hexon protein , comprising the following steps:using two primers to amplify Hexon-HVR full-length gene sequence as to get a nucleotide sequence consisting of SEQ ID NO:3; wherein the two primers are SEQ ID NO:1 and SEQ ID NO:2;inserting the nucleotide sequence into a plasmid vector; and{'i': 'Escherichia coli', 'transferring the vector with the nucleotide sequence into as to express the adenovirus hexon protein.'}2. The method according to claim 1 , wherein the Hexon-HVR full-length gene sequence is the serial number of AC_000008.1 in NCBI.3. The method according to claim 1 , wherein after the adenovirus hexon protein is expressed claim 1 , it is purified by the following steps:i) the inclusion body which have expressed is collected by centrifuging at 8000 rpm for 10 min;ii) the obtained inclusion body is resuspended with 15 ml inclusion body washing solution, and slowly stirred at 37° C. for 30 min, then centrifuged at 4000 rpm for 30 min, and rewashing again after collecting the inclusion body pellet;iii) after centrifugation and washing twice with washing solution, the inclusion body is resuspended with 15 ml inclusion body purification solution A, slowly stirred at 37° C. for 30 min, then centrifuged at 8000 rpm for 10 min, and collecting the supernatant;{'sub': '2', 'iv) the supernatant is added to a well-balanced nickel column (nickel column was balanced by 3 times of column volumes of ddHO and 3 times of column volumes of inclusion body purification solution A), ...

NOVEL ADENOVIRUS ISOLATED FROM TITI MONKEYS

Provided is a Titi Monkey Adenovirus (TMAdV) that can infect both human and non-human primates. Further provided are nucleic acid sequences, proteins, expression vectors and host cells, anti-TMAdV antibodies, vaccines, compositions, methods of detecting TMAdV, methods for assaying for anti-TMAdV compounds, and methods for treating or preventing a TMAdV infection. 1. An isolated nucleic acid comprising a nucleotide sequence at least 100 nucleotides in length that has at least 90% sequence identity over its length to SEQ ID NO:1 or its complement.2. The nucleic acid of claim 1 , wherein the nucleotide sequence comprises at least 95% identity over its length to SEQ ID NO:1.3. The nucleic acid of claim 1 , wherein the nucleotide sequence comprises at least 90% identity over the full length of SEQ ID NO:1.4. The nucleic acid of claim 1 , wherein the nucleotide sequence comprises at least 95% identity over the full length of SEQ ID NO:15. The nucleic acid of claim 1 , wherein the nucleotide sequence comprises SEQ ID NO:1.6. An isolated expression vector comprising the nucleic acid of .7. An isolated host cell comprising the expression vector of .8. An isolated nucleic acid comprising a nucleotide sequence at least 100 nucleotides in length and has at least 90% sequence identity to an open reading frame selected from the group consisting of SEQ ID NOs:2-37.9. The nucleic acid of claim 8 , wherein the nucleotide sequence comprises at least 95% identity to the open reading frame encoded by the nucleotide sequence selected from the group consisting of SEQ ID NOs:2-37.10. The nucleic acid of claim 8 , wherein the nucleotide sequence comprises the open reading frame encoded by the nucleotide sequence selected from the group consisting of SEQ ID NOs:2-37.11. An isolated protein encoded by the nucleotide sequence of .12. An isolated antibody that specifically binds to the protein of .13. The antibody of claim 12 , wherein the antibody is a polyclonal antibody.14. The antibody of ...

EMULSIFIED VACCINE TO OBTAIN FORMULATIONS OF CONCENTRATED IGY IMMUNOGLOBULINS; PROCESSES AND USES FOR THE SAME

The present invention relates to a therapy for treating or preventing several diseases in animals, based on the administration of a highly concentrated avian derived immunoglobulins formulation, obtained from the egg yolk from hens previously hiper-immunized with a vaccine formulation comprising infectious agents or toxins antigens, a light mineral oil and a particulate adjuvant. 1. An emulsified vaccine formulation comprising: (i) antigens , (ii) a light mineral oil and (iii) a particulate adjuvant selected from the group consisting of biodegradable polymer particles , micro-particles or nano-particles.2. The emulsified vaccine formulation of claim 1 , wherein the antigens are derived from one or more different strains of one or more viruses.3. The emulsified vaccine formulation of claim 2 , wherein the virus is the PRRS virus.4. The emulsified vaccine formulation of claim 3 , wherein the PRRS virus isolated strains have an ORF5 gen nucleotide sequence selected from the group consisting of SEQ. ID. NO: 1 claim 3 , SEQ. ID. NO: 2 claim 3 , SEQ. ID. NO: 3 claim 3 , SEQ. ID. NO: 4 claim 3 , SEQ. ID. NO: 5 claim 3 , SEQ. ID. NO: 6 and SEQ. ID. NO: 7.5. The emulsified vaccine formulation of claim 2 , wherein the virus is the Porcine Epidemic Diarrhea (PED) virus.6. The emulsified vaccine formulation of claim 2 , wherein the virus is the White Spot Syndrome Baculovirus Complex virus.7. The emulsified vaccine formulation of claim 1 , wherein the antigens are derived from one or more different strains or one or more bacteria.8Staphylococcus aureus, Streptococcus agalactiae, Escherichia coli, Corynebacterium pyogenes y Mycoplasma bovis.. The emulsified vaccine formulation of claim 7 , wherein the antigens are derived from one or more different strains or one or more bacteria selected from the group consisting of:9Actinobacillus pleuropneumoniae.. The emulsified vaccine formulation of claim 7 , wherein the antigens are derived from one or more different strains of10. The ...

Biological Therapeutics for Infection-Relating Disorders or Conditions

The present invention discloses products and the methods of uses of the products for preventing and treating infectious diseases and the disorders or conditions inducible by harmful antibodies. The harmful antibodies are induced during infection, or vaccination, or use of therapeutic antibodies. The products of the present disclosure comprise immunoglobulin products, serum or plasma, specific antibodies to viral pathogens. 1: A therapeutic product for treating and preventing an infection caused by a viral pathogen or a disease or condition caused by a harmful antibody , comprising:(a) an N-acetylneuraminic acid; and(b) at least one of a specific antibody to a viral pathogen, an immunoglobulin, and serum or plasma,wherein the harmful antibody is induced by an infection, a vaccination, or a passively introduced therapeutic antibody,wherein the disease or condition caused by the harmful antibody comprises an infectious disease, a serious adverse reaction to a vaccine or a therapeutic antibody, an infection-related autoimmune disease, an allergy, inflammation, or an infection-related tumor, andwherein the immunoglobulin, serum, or plasma is obtained from a healthy individual.2: The therapeutic product of claim 1 , wherein the viral pathogen is an influenza virus claim 1 , a hepatitis C virus claim 1 , a hepatitis B virus claim 1 , a respiratory syncytial virus claim 1 , an adenovirus claim 1 , or a rotavirus.3: The therapeutic product of claim 1 , wherein the serious adverse reaction is Guillain-Barre syndrome-like condition claim 1 , death claim 1 , abortion claim 1 , immature or delayed delivery claim 1 , fetal death claim 1 , or neonatal death.4: The therapeutic product of claim 1 , wherein the infection is an influenza infection and the vaccination is influenza vaccination.5: The therapeutic product of claim 1 , wherein the product comprises about 0.001 g to about 100 g of immunoglobulin or about 0.1 mL to 1000 mL of serum or plasma.6: The therapeutic product of ...

Cytomegalovirus antigens and uses thereof

The disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.

INTEGRAL MEMBRANE PROTEIN DISPLAY ON POXVIRUS EXTRACELLULAR ENVELOPED VIRIONS

This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest. 1. An isolated polynucleotide comprising:(a) a first nucleic acid fragment that encodes an integral membrane protein (IMP) or fragment thereof, wherein the IMP or fragment thereof comprises at least one extra-membrane region, at least one transmembrane domain and at least one intra-membrane region, and wherein a portion of the first nucleic acid fragment encoding at least one intra-membrane region is situated at the 5′ or 3′ end of the first nucleic acid fragment; and(b) a second nucleic acid fragment that encodes a vaccinia virus F13L protein comprising the amino acid sequence SEQ ID NO: 1 or functional fragment thereof, wherein the second nucleic acid fragment is fused in frame to a portion of the first nucleic acid fragment that encodes an intra-membrane region of the IMP;wherein a poxvirus infected cell comprising the polynucleotide can express an IMP-F13L fusion protein as part of the outer envelope membrane of an extracellular enveloped virion (EEV).2. The polynucleotide of claim 1 , wherein the IMP is a multi-pass membrane protein comprising at least two transmembrane domains.3. The polynucleotide of claim 2 , wherein the IMP has an odd number of transmembrane domains claim 2 , wherein the 5′ end of the first nucleic acid fragment encodes an extra-membrane region claim 2 , wherein the 3′ end of the first nucleic acid fragment encodes an intra-membrane region claim 2 , and wherein the 5′ end of the second polynucleotide is fused to the 3′ end of the first nucleic acid fragment.4. The polynucleotide of claim 3 , wherein the IMP comprises a G-protein coupled receptor (GPCR).5. The polynucleotide of claim 4 , wherein the IMP is the human frizzled-4 protein (FZD4) ...

Porcine Circovirus Type 2 (PCV2), Immunogenic Composition Containing the Same, Test Kit, and Application Thereof

The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain. 1. A porcine circovirus type 2 (PCV2) virus , comprising the genome sequence of SEQ ID NO: 1.2. The porcine circovirus type 2 (PCV2) virus of claim 1 , which was deposited at the China Center for Type Culture Collection (CCTCC) under accession No. V201117.3. The porcine circovirus type 2 (PCV2) virus of claim 1 , wherein the PCV2 virus is able to cause cytopathic effect (CPE) in PK-15 cell line or its derivative cell lines.4. An immunogenic composition claim 1 , comprising the porcine circovirus type 2 (PCV2) virus of claim 1 , wherein the PCV2 virus is attenuated claim 1 , or a subunit claim 1 , a DNA construct claim 1 , or other forms derived and produced from the PCV2 of .5. The immunogenic composition of claim 4 , further comprising a pharmaceutically acceptable vehicle.6. The immunogenic composition of claim 5 , wherein the pharmaceutically acceptable vehicle is an adjuvant.7. The immunogenic composition of claim 4 , further comprising at least one pathogen antigen selected from the group consisting of antigen of Swine influenza virus (SIV) claim 4 , antigen of porcine reproductive and respiratory syndrome virus (PRRSV) claim 4 , antigen of mycoplasma claim 4 , antigen of porcine parvovirus (PPV) claim 4 , antigen of erysipelas claim 4 , and antigen of pseudorabies virus.8. A method of protecting a pig from porcine circovirus type 2 infection claim 4 , comprising inoculating the pig with an immunogenic composition comprising a porcine circovirus type 2 (PCV2) virus having the genome sequence of SEQ ID NO: 1.9. The method of claim 8 , wherein the porcine circovirus type 2 (PCV2) virus is inactivated by at least one of formaldehyde claim 8 , paraformaldehyde claim 8 , beta-propiolactone (BPL) claim 8 , and binary ethyleneimine (BEI).10. The ...

Porcine circovirus type 3 immunogenic compositions and methods of making and using the same

A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.

Treatment of ocular neovascularization using anti-vegf proteins

The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.

PATHOGEN DETECTION BY SERS NANOPARTICLES

A phage specific antibody presenting particle, devices and methods related to detection of phage amplification are provided. Specifically, described herein are compositions and methods for detecting bacteria using an antibody that recognized A511 anti-phage, wherein the antibody is conjugated to a nanoparticle that can be detected by surface-enhanced Raman scattering (SERS). 1Listeria. A phage-specific antibody-presenting particle comprising:a gold metal core;a coating comprising at least one Raman active reporter molecule attached to the surface of the metal core;a glass coating surrounding said coating; anda phage-specific antibody attached to the surface of said glass coating.2. The antibody-presenting particle of claim 1 , wherein the Raman active reporter is trans-1 claim 1 ,2-bis(4-pyridyl)-ethylene.3. The antibody-presenting particle of claim 2 , wherein the glass coating comprises SiO functionalized with thiol groups.4. The antibody-presenting particle of claim 1 , further comprising a metal shell overlaying the core.5. The antibody-presenting particle of claim 4 , wherein the metal shell is comprised of Au/AuS.6. The antibody-presenting particle of claim 1 , wherein the core is a sphere with a diameter between 15-200 nm.7. The antibody-presenting particle of claim 6 , wherein the core has a diameter of about 50-60 nm.8Listeria. The antibody-presenting particle of claim 1 , wherein the phage specific antibody recognizes phage A511.9. The antibody-presenting particle of claim 8 , wherein the phage specific antibody is polyclonal10. The antibody-presenting particle of claim 8 , wherein the phage specific antibody is monoclonal.11Listeria. A method of creating a phage-specific antibody-presenting nanoparticle the method comprising:combining a sulfosuccinimidyl crosslinker with a sulfonic acid buffer to create a crosslinker mixture;{'i': 'Listeria', 'combining the phage specific antibody with the crosslinker mixture to create an antibody mixture;'}combining the ...

Method of Treating and Preventing Infectious Diseases Using Colostrum

A method of treating and/or preventing infectious disease in mammals, such as canines, includes administering an effective amount of a colostral composition to a mammal which has been produced by a donor mammal and includes at least one type of antibody having a binding specificity for at least one pathogen. The at least one type of antibody is generated by the donor mammal in response to being challenged with at least one challenge material. 1. A method of treating and/or preventing infectious disease in mammals , the method comprising:collecting a colostral composition from a donor animal, the colostral composition including at least one type of antibody having a binding specificity for at least one pathogen, the at least one type of antibody being generated by the donor mammal in response to being challenged with at least one challenge material,freezing the collected colostral composition;sterilizing the frozen colostral composition by gamma irradiation;thawing the sterilized colostral composition; andadministering an effective amount of the thawed colostral composition to a mammal.23-. (canceled)4. The method of claim 1 , wherein the donor species is immunized to generate the antibodies.5. The method of claim 1 , wherein the non-canine donor species is challenged during pregnancy.6. The method of claim 1 , wherein the non-canine donor species is selected from a group comprising cow claim 1 , goat claim 1 , and sheep.7. The method of claim 1 , wherein the colostral composition is administered orally to the mammal.8. The method of claim 1 , wherein the colostral composition is administered to the mammal within approximately 48 hours of birth.9. The method of claim 1 , wherein the mammal is a canine claim 1 , andwherein the colostral composition is administered to the canine in response to being infected by a canine pathogen.10. The method of claim 9 , wherein the canine pathogen comprises canine parvovirus.11. A method of treating and/or preventing infectious ...

Methods and compositions for combination immunotherapy

Methods and compositions for generating immune responses using adenovirus vectors that allow multiple vaccinations or in combination with other therapy and vaccinations in individuals with preexisting immunity to adenovirus are provided.

MONOCLONAL ANTIBODY SPECIFIC TO PCV2 AND METHOD FOR DIAGNOSING PMWS USING SAME

The present invention relates to a monoclonal antibody specific to porcine circovirus 2 (PCV2) and a method for diagnosing post-weaning multi-systemic wasting syndrome (PMWS) using the same. More specifically, the present invention relates to monoclonal antibodies C4-1 and C4-8 of scFV-human Cκ fusion recombinant protein, which specifically binds to a decoy epitope of porcine circovirus 2, and to a method for diagnosing post-weaning multi-systemic wasting syndrome using the same. The monoclonal antibody of the present invention makes it possible to determine whether an antibody against PCV2 is a neutralizing antibody by a vaccine antigen or an antibody induced by immune decoy. 1. A monoclonal antibody specific to porcine circovirus 2 (PCV2) , wherein the monoclonal antibody is scFV-human Cκ fusion recombinant protein that specifically binds to a decoy epitope of PCV2.2. The monoclonal antibody of claim 1 , wherein the ScFV-human Cκ fusion recombinant protein claim 1 , which specifically binds to a decoy epitope of PCV2 claim 1 , is C4-1 claim 1 , C4-8 claim 1 , or C4-1 and C4-8.3. The monoclonal antibody of claim 1 , wherein the decoy epitope of the PCV2 is 12 amino acids positioned from the 169to the 180.4. The monoclonal antibody of claim 3 , wherein the amino acids are STIDYFQPNNKR (SEQ ID NO: 11).5. A reagent for diagnosing post-weaning multi-systemic wasting syndrome (PMWS) claim 3 , comprising an antigen for diagnosis claim 3 , a monoclonal antibody for capturing the antigen for diagnosis claim 3 , a label for detection claim 3 , a monoclonal antibody to which the label for detection is bound claim 3 , and a reagent for measuring the activity of the label for detection claim 3 , wherein the monoclonal antibody for capturing the antigen for diagnosis is an scFV-human Cκ fusion recombinant protein which specifically binds to the decoy epitope of porcine circovirus 2 (PCV2).6. The PMWS reagent of claim 5 , wherein the ScFV-human Cκ fusion recombinant protein ...

METHODS AND COMPOSITIONS FOR ANTIBODY-EVADING VIRUS VECTORS

The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo. 1207-. (canceled)209. The recombinant AAV vector of claim 208 , wherein the capsid protein with the substitutions of one or more of (a)-(c) has an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:1.210. The recombinant AAV vector of claim 208 , wherein the capsid protein comprises at least one amino acid deletion relative to SEQ ID NO: 1.211. The recombinant AAV vector of claim 208 , wherein the capsid protein comprises at least one amino acid insertion relative to SEQ ID NO:1.212. The recombinant AAV vector of claim 208 , wherein the one or more substitutions inhibit neutralization of infectivity of the AAV vector and/or inhibit binding of an antibody to the AAV vector claim 208 , wherein the antibody binds to a capsid protein comprising the amino acid sequence of SEQ ID NO:1.213. The recombinant AAV vector of claim 212 , wherein the antibody is a mouse monoclonal antibody selected from the group consisting of ADK1a claim 212 , 4E4 and 5H7.214. The recombinant AAV vector of claim 213 , wherein the antibody is ADK1a.215. The recombinant AAV vector of claim 213 , wherein the antibody is 4E4.216. The recombinant AAV vector of claim 213 , wherein the antibody is 5H7.217. The recombinant AAV vector of claim 208 , wherein the nucleic acid encodes a heterologous polypeptide.218. The recombinant AAV vector of claim 217 , wherein the heterologous polypeptide is a therapeutic polypeptide.219. The recombinant AAV vector of claim 208 , wherein the nucleic acid encodes heterologous RNA sequence.220. The recombinant virus vector of claim 219 , wherein the heterologous RNA is a functional RNA.221. A method of producing a ...

Compositions of exosomes and aav

The present disclosure relates to extracellular vesicles, e.g., exosomes, comprising an AAV and a scaffold protein. In some aspects, the AAV is in the lumen of the extracellular vesicle. In some aspects, the AAV is associated with the luminal surface of the extracellular vesicle. In some aspects, the AAV is associated with the exterior surface of the extracellular vesicle. Also provided herein are methods for producing the exosomes and methods for using the exosomes to treat and/or prevent diseases or disorders.

Canine health product containing antibodies against canine parvovirus type 2

FIELD: biotechnology. SUBSTANCE: invention relates to biotechnology. This invention is a composition that includes antibodies against one or more specified viruses, bacteria and/or pathogens for use to improve a dog's health, wherein the composition is administered during the first 24 hours of a dog’s life or between 24 hours and up to 90 days, corresponding to the age of the dog. EFFECT: invention allows to improve the health and zootechnical characteristics of a dog. 8 cl, 3 dwg, 1 tbl, 1 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 678 132 C2 (51) МПК C07K 16/06 (2006.01) A61K 39/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК C07K 16/06 (2018.08); A61K 39/00 (2018.08) (21)(22) Заявка: 2016103915, 09.07.2014 (24) Дата начала отсчета срока действия патента: Дата регистрации: 23.01.2019 (73) Патентообладатель(и): МАРС, ИНКОРПОРЕЙТЕД (US) (43) Дата публикации заявки: 14.08.2017 Бюл. № (45) Опубликовано: 23.01.2019 Бюл. № 3 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 09.02.2016 (86) Заявка PCT: EP 2014/064711 (09.07.2014) (87) Публикация заявки PCT: 2 6 7 8 1 3 2 WO 2015/004181 (15.01.2015) Адрес для переписки: 129090, Москва, ул. Б.Спасская, 25, строение 3, ООО "Юридическая фирма Городисский и Партнеры" (54) ПРОДУКТ ДЛЯ ЗДОРОВЬЯ СОБАК, СОДЕРЖАЩИЙ АНТИТЕЛА ПРОТИВ СОБАЧЬЕГО ПАРВОВИРУСА ТИПА 2 (57) Реферат: Изобретение относится к области вводят в течение первых 24 часов жизни собаки биотехнологии. Изобретение представляет собой или в период между 24 часами и до 90 дней, композицию, которая включает антитела против соответствующих возрасту собаки. Изобретение одного или нескольких определенных вирусов, позволяет улучшить здоровье и зоотехнические бактерий и/или патогенов для применения для характеристики собаки. 7 з.п. ф-лы, 3 ил., 1 табл., улучшения здоровья собаки, где композицию 1 пр. (56) (продолжение): due to Canine parvovirus-2 by specific antibody from chicken egg yolk, The ...

抗非洲猪瘟病毒p30蛋白单克隆抗体、制备方法及B细胞表位筛选和鉴定

本发明公开了一种抗非洲猪瘟病毒p30蛋白单克隆抗体、制备方法及B细胞表位筛选和鉴定，属于基因工程技术领域，本发明设计并构建能够稳定表达ASFV p30蛋白的H22细胞株和HEK293T细胞株，以稳定表达p30蛋白H22细胞作为免疫原免疫小鼠，利用细胞融合技术，以稳定表达p30蛋白HEK293T细胞作为检测原，通过免疫过氧化物酶单层细胞试验，筛选得到抗ASFV p30蛋白的单克隆细胞株10D7，该细胞株产生的单克隆抗体可特异性识别并结合p30蛋白上的 171 YGTPLKEEEK 180 至 176 KEEEKEVVRL 185 序列区域，有助于了解抗原‑抗体之间的相互作用，对ASFV的检测和诊断具有重要意义。

Canine parvovirus strain CPV-YH and applications thereof

本发明提供一株犬细小病毒毒株CPV‑YH，属于微生物技术领域。所述犬细小病毒毒株CPV‑YH的保藏号为CGMCC NO.12990。本发明还提供所述的犬细小病毒毒株CPV‑YH在制备犬细小病毒疫苗方面的用途，以及在制备犬细小病毒诊断试剂方面的用途。基于所述犬细小病毒毒株CPV‑YH，本发明还提供一种用于预防和/或治疗犬细小病毒所致疾病的疫苗组合物，和一种用于检测犬细小病毒强毒株和/或诊断犬细小病的试剂。本发明不仅为了解和掌握目前流行毒株的变异情况提供了新的内容和方向，同时满足了犬细小病领域亟需疫苗开发所需的新毒株的筛选需求，为疫苗开发提供了新的优质的原材料和选择空间。

二重特異性抗体を用いる免疫応答を促進する方法

(57)【要約】 本発明は、患者に免疫応答を誘導する方法を提供する。本方法は、FcγRIIIおよび第２の抗原を認識および結合し得る二重特異性分子を投与する工程を包含する。第２の抗原は、ガン抗原、ウイルス抗原、真菌抗原、寄生虫の抗原、または毒素であり得る。第２の抗原は、本発明の方法が実施されるときにおいて、患者中に存在し得るか、または存在しなくてもよい。

Canine parvovirus nano antibody CPV-VHH-E3 and application thereof

本发明公开了一种犬细小病毒纳米抗体CPV‑VHH‑E3及其应用，属于免疫学技术领域。所述纳米抗体CPV‑VHH‑E3的重链可变区序列由如SEQ ID NO：1所示氨基酸序列组成，编码所述的纳米抗体CPV‑VPP‑E3的基因的核苷酸序列如SEQ ID NO：2所示。本发明通过噬菌体展示技术构建了犬细小病毒的纳米抗体免疫文库，通过筛选获得特异性抗CPV纳米抗体CPV‑VHH‑E3，通过试验验证该纳米抗体可以特异性结合CPV，有望开发出可用于CPV的临床诊断和治疗的纳米抗体新型制剂，为纳米抗体应用于兽用生物制品领域提供一定的理论储备。

anti-African swine fever virus p30 protein monoclonal antibody, preparation method and B cell epitope screening and identification

本发明公开了一种抗非洲猪瘟病毒p30蛋白单克隆抗体、制备方法及B细胞表位筛选和鉴定，属于基因工程技术领域，本发明设计并构建能够稳定表达ASFV p30蛋白的H22细胞株和HEK293T细胞株，以稳定表达p30蛋白H22细胞作为免疫原免疫小鼠，利用细胞融合技术，以稳定表达p30蛋白HEK293T细胞作为检测原，通过免疫过氧化物酶单层细胞试验，筛选得到抗ASFV p30蛋白的单克隆细胞株10D7，该细胞株产生的单克隆抗体可特异性识别并结合p30蛋白上的 171 YGTPLKEEEK 180 至 176 KEEEKEVVRL 185 序列区域，有助于了解抗原‑抗体之间的相互作用，对ASFV的检测和诊断具有重要意义。

HEALTHY DOG PRODUCT CONTAINING ANTIBODIES AGAINST DOG PARVIRUS TYPE 2

А 2016103915 ко РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (10 = (50) МПК Аб1К 39/395 (2006.01) (21)(22) Заявка: 2016103915, 09.07.2014 Приоритет(ы): (30) Конвенционный приоритет: 09.07.2013 ЕР 13305976.6; 13.03.2014 СВ 1404503.3 (43) Дата публикации заявки: 14.08.2017 Бюл. № 23 (85) Дата начала рассмотрения заявки РСТ на национальной фазе: 09.02.2016 (86) Заявка РСТ: ЕР 2014/064711 (09.07.2014) (87) Публикация заявки РСТ: УГО 2015/004181 (15.01.2015) Адрес для переписки: 129090, Москва, ул. Б.Спасская, 25, строение 3, ООО "Юридическая фирма Городисский и Партнеры" (71) Заявитель(и): МАРС, ИНКОРПОРЕЙТЕД (0$) (72) Автор(ы): ФЕЖЬЕ Александр (ЕК), ШАСТАН Сильви (ЕК), МИЛА Ханна (ЕК), ГРЕЛЛЕ Орельен (ЕК) (54) ПРОДУКТ ДЛЯ ЗДОРОВЬЯ СОБАК, СОДЕРЖАЩИЙ АНТИТЕЛА ПРОТИВ СОБАЧЬЕГО ПАРВОВИРУСА ТИПА 2 (57) Формула изобретения ИЗМЕНЕННАЯ ФОРМУЛА ИЗОБРЕТЕНИЯ 1. Композиция, содержащая антитела против собачьего парвовируса типа 2 в комбинации с одним из следующих: собачий коронавирус, А.сой, собачий герпесвирус, необязательно также в комбинации с ВогавеЙа Бгопси5ерйса или Слагоайа/! или содержащая антитела против одного или нескольких из следующих; собачий вирус парагриппа, собачий вирус чумы, Аденовирус типа 1, 5перюсосс, (ар ососс! или [во5рога для применения для улучшения здоровья собаки, причем композицию вводят в первые Стр.: 1 па 1650191 0сС У А 2016103915 ко 24 ч жизни или в последующие 24 ч. 2. Композиция для применения по п.1, также содержащая гидролизованный углевод и/или масло. 3. Композиция для применения по п.1 в форме спрея, жидкости, мусса или геля. 4. Композиция для применения по любому из пп.1-3, где композиция включает антитела против одного или нескольких из вирусов и антитела против А. сой. 5. Композиция по любому из пи. 1-3, где композиция содержит антитела против собачьего коронавируса и/или аденовируса тира 1. 6. Композиция для применения по любому из пи. 1-3, где композицию вводят дважды с ...

Bifunctional molecules for targeting gene delivery and vectors conjugated therewith

アデノウイルス遺伝子送達粒子などの送達ベクターを選択した細胞種にターゲッティングする方法および産物が提供される。本方法はベクター粒子表面のタンパク質、またターゲッティングされた細胞表面タンパク質と特異的に複合化する二官能性分子によるターゲッティングによるものである。ターゲッティングされた細胞表面タンパク質はホスファチジルイノシトール−３−ＯＨキナーゼを活性化するいずれのものであってもよい。該二官能性分子、組成物、キット、ならびに遺伝子治療のためのベクター／二官能性分子の製造および使用方法が提供される。

Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases

Method of promoting an immune response with a bispecific antibody

Canine parvovirus nano antibody CPV-VHH-E3 and application thereof

本发明公开了一种犬细小病毒纳米抗体CPV‑VHH‑E3及其应用，属于免疫学技术领域。所述纳米抗体CPV‑VHH‑E3的重链可变区序列由如SEQ ID NO：1所示氨基酸序列组成，编码所述的纳米抗体CPV‑VPP‑E3的基因的核苷酸序列如SEQ ID NO：2所示。本发明通过噬菌体展示技术构建了犬细小病毒的纳米抗体免疫文库，通过筛选获得特异性抗CPV纳米抗体CPV‑VHH‑E3，通过试验验证该纳米抗体可以特异性结合CPV，有望开发出可用于CPV的临床诊断和治疗的纳米抗体新型制剂，为纳米抗体应用于兽用生物制品领域提供一定的理论储备。

Torque teno virus(ttv) isolates and compositions

본 발명은 토크 테노 바이러스("TTV")의 신규 뉴클레오티드 및 아미노산 서열(이들의 신규 유전자형을 포함함)에 관한 것으로, 이들은 모두 돼지 및 다른 동물에서 질병을 치료 및 예방하기 위한 백신의 제조에 유용하다. 본 발명의 실시에 따라 제공된 백신은 다중 돼지 TTV 유전자형 및 분리물에 대해 효과적이다. 바이러스의 증식 및 백신의 제조에 유용한 감염성 클론과 마찬가지로, 진단 및 치료용 다클론성 및 단클론성 항체도 본 발명의 한 특징이다. 본 발명의 특히 중요한 측면은 TTV ORF1 단백질 또는 이의 펩티드 단편을 항원으로 제공하는 백신을 포함한다.

Chimeric antigen receptor targeting oncolytic virus-derived protein, cell expressing the same, and use thereof

본 발명은 항암바이러스 유래 단백질을 표적으로 하는 키메라 항원 수용체, 이를 발현하는 면역세포 및 이들의 용도에 관한 것으로서, 본 발명은 특히 백시니아 바이러스로 감염된 암세포의 세포 표면에 발현되는 A56 단백질을 표적으로 하는 키메라 항원 수용체, 및 이를 발현하는 면역세포 및 이들의 용도에 관한 것이다. 본 발명의 키메라 항원 수용체를 발현하는 면역세포는 암세포의 세포 표면에 특이적으로 발현되는 A56 단백질을 효과적으로 표적화함으로써 항암바이러스에 감염되었음에도 잔존하는 암세포에 대한 표적 치료를 가능케 하여 효과적인 항암 요법을 제공할 수 있다. 본 발명의 키메라 항원 수용체를 발현하는 면역세포는 A56 단백질에 특이적으로 활성화 및 증식 능력을 높이고 우수한 세포독성 효과를 발휘하여 A56 단백질을 발현하는 암세포에 대해 효과적인 항암요법을 제공할 수 있다. 바람직하게는, 항암바이러스와 병용되며, 항암바이러스의 항암효과를 증진시킬 수 있는 약제(예: 히드록시유레아, 림프구 제거 조절을 위한 화학요법제(예: 사이클로포스파미드, 플루다라빈 등), 또는 면역치료제)가 추가로 병용될 수 있다. The present invention relates to a chimeric antigen receptor targeting an anticancer virus-derived protein, immune cells expressing the same, and uses thereof. Chimeric antigen receptors, and immune cells expressing the same, and uses thereof. Immune cells expressing the chimeric antigen receptor of the present invention effectively target the A56 protein specifically expressed on the cell surface of cancer cells, thereby enabling targeted treatment of cancer cells remaining even after infection with an anti-cancer virus, thereby providing effective anti-cancer therapy. have. Immune cells expressing the chimeric antigen receptor of the present invention can provide effective anticancer therapy against A56 protein-expressing cancer cells by enhancing activation and proliferation ability specifically for A56 protein and exhibiting excellent cytotoxic effects. Preferably, it is used in combination with an anticancer virus, and an agent capable of enhancing the anticancer effect of the anticancer virus (eg, hydroxyurea, a chemotherapeutic agent for controlling lymphocyte removal (eg, cyclophosphamide, fludarabine, etc.); or immunotherapeutic agents) may be additionally used in combination.

Patent RU2016103915A3

`”ВУ“” 2016103915” АЗ Дата публикации: 21.03.2018 Форма № 18 ИЗИМ-2011 Федеральная служба по интеллектуальной собственности Федеральное государственное бюджетное учреждение 5 «Федеральный институт промышленной собственности» (ФИПС) ОТЧЕТ О ПОИСКЕ 1. . ИДЕНТИФИКАЦИЯ ЗАЯВКИ Регистрационный номер Дата подачи 2016103915/10(006187) 09.07.2014 РСТ/ЕР2014/064/7 11 09.07.2014 Приоритет установлен по дате: [ ] подачи заявки [ ] поступления дополнительных материалов от к ранее поданной заявке № [ ] приоритета по первоначальной заявке № из которой данная заявка выделена [ ] подачи первоначальной заявки № из которой данная заявка выделена [ ] подачи ранее поданной заявки № [Х] подачи первой(ых) заявки(ок) в государстве-участнике Парижской конвенции (31) Номер первой(ых) заявки(ок) (32) Дата подачи первой(ых) заявки(ок) (33) Код страны 1. 13305976.6 09.07.2013 ЕР* 2. 1404503.3 13.03.2014 СВ Название изобретения (полезной модели): [Х] - как заявлено; [ ] - уточненное (см. Примечания) ПРОДУКТ ДЛЯ ЗДОРОВЬЯ СОБАК, СОДЕРЖАЩИЙ АНТИТЕЛА ПРОТИВ СОБАЧЬЕГО ПАРВОВИРУСА ТИПА 2 Заявитель: МАРС, ИНКОРПОРЕЙТЕД, 0$ 2. ЕДИНСТВО ИЗОБРЕТЕНИЯ [Х] соблюдено [ ] не соблюдено. Пояснения: см. Примечания 3. ФОРМУЛА ИЗОБРЕТЕНИЯ: [Х] приняты во внимание все пункты см. п см. Примечания [ ] приняты во внимание следующие пункты: [ ] принята во внимание измененная формула изобретения (см. Примечания) 4. КЛАССИФИКАЦИЯ ОБЪЕКТА ИЗОБРЕТЕНИЯ (ПОЛЕЗНОЙ МОДЕЛИ) (Указываются индексы МПК и индикатор текущей версии) Аб1К 39/395 (2006.01) 5. ОБЛАСТЬ ПОИСКА 5.1 Проверенный минимум документации РСТ (указывается индексами МПК) 5.2 Другая проверенная документация в той мере, в какой она включена в поисковые подборки: 5.3 Электронные базы данных, использованные при поиске (название базы, и если, возможно, поисковые термины): Е-Габгагу, Езрасепев, Рабеагсв, РАТЕМТСОРЕ, КУРТО, МСВТ, ЕМВГ-ЕВ1, Соозе, Соозе эспо[аг, РиБМеа, ОРТО, Зслепсе\гесе 6. ДОКУМЕНТЫ, ОТНОСЯЩИЕСЯ К ПРЕДМЕТУ ПОИСКА Кате- Наименование документа с указанием ( ...

Small antibody-like single chain proteins

The present invention provides a "ASCP-body" that comprises a bottomside epitope binding domain ("BEBD") comprising four Bottomside Binding Regions (BBR1, BBR2, BBR3, and BBR4). This epitope binding domain is in addition to the topside epitope binding domain (TEBD) formed by the three Complementarity Determining Regions (CDR1, CDR2, and CDR3). The invention encompasses mono-specific, bi-specific and multi-specific, and mono-valent, bi-valent and multi-valent ASCP-bodies. The invention also encompasses fusion proteins in which one or more ASCP-bodies with a BEBD is conjugated to one or more ASCP-bodies with a BEBD and, optionally, a TEBD; to one or more ASCP- bodies with a TEBD and, optionally, a BEBD; or to one or more non-ASCP-body entity(ies). The various ASCP-bodies in the bi-specific and multi-specific ASCP-bodies and fusion proteins may all bind to the same epitopes or antigens or may bind to different epitopes or antigens.

Antibody composition with altered Fab sialic acid addition

Preparation of feline parvovirus recombinant protein and monoclonal antibody thereof

本发明属于生物工程技术领域。本发明涉及一种猫细小病毒重组蛋白，该猫细小病毒重组蛋白包含猫细小病毒(FPV)抗原的两个优势表位，为提高该重组蛋白在原核表达系统中的产量，采用大肠杆菌偏爱密码子将该重组蛋白氨基酸序列转换为对应的核苷酸序列，化学合成该核苷酸序列并构建重组表达载体。本发明还涉及该猫细小病毒重组蛋白单克隆抗体的制备，经过免疫、细胞融合及多轮筛选后得到杂交瘤细胞株，纯化单克隆抗体并分别标记胶体金颗粒，通过正交实验确定最佳单抗配对组合，可用于猫细小病毒感染的早期诊断。

Recombinant human antibodies for therapy and prevention of polyomaviruses-related diseases

提供了新的人源化抗体以及与其相关的方法，该抗体特异性识别多瘤病毒多肽，优选能够结合至JC病毒(JCV)和/或BK病毒(BKV)类型的多瘤病毒。另外，公开了与抗体相关的测定和试剂盒，该抗体对于优选JCV和/或BKV类型的多瘤病毒、多瘤病毒VP1和或多瘤病毒VP1病毒样颗粒(VLP)是特异性的。人源化抗体以及其结合片段、衍生物和变体以被用于多瘤病毒靶向的免疫治疗和诊断的药物和诊断组合物中。

Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes

The present invention relates to an Epstein-Barr virus-like particle (EB-VLP) substantially free of Epstein-Barr Virus (EBV) DNA. The present invention also relates to a polynucleotide comprising an EBV genome a) lacking at least one expressible gene selected from the group consisting of the BFLF1 gene, the BBRF gene, the BGRF1 gene, the BDRF1 gene, the BALF3 gene, the BFRF1A gene, and the BFRF1 gene, and b) producing the EB-VLP of the invention in a suitable host cell. The present invention further relates to a vector and a host cell comprising the polynucleotide of the invention as well to a method of manufacturing the EB-VLPs, a method of manufacturing a vaccine thereof, a vaccine and a composition comprising the EB-VLPs.

A kind of neutrality Humanized monoclonal antibodies of human 3-type adenovirus and its preparation method and application

本发明提供了一种人3型腺病毒的中和性人源化单克隆抗体及其制备方法和应用，该抗体基因含有如SEQ ID NO：43和44所述序列。本发明还提供了制备方法：扩增鼠源性单克隆抗体的轻链和重链序列；将轻链序列与人轻链恒定区序列和轻链信号肽连接，将重链序列与人重链恒定区序列和重链信号肽连接，轻链信号肽由人骨粘连蛋白信号肽所替换，重链信号肽由前胰蛋白酶信号肽所替换；再分别插入真核表达载体中，转染到细胞系。本发明提供的抗体基因含有如SEQ ID NO：43和44所述序列，并通过更换信号肽、提供适合的信号肽的组合，提高了人3型腺病毒中和性人源化单克隆抗体的产量，对研制高产量的可治疗感染性疾病的单抗有着重要意义。

Modified immunoglobulins with altered FcRn

Anti-viral engineered immunoglobulins

The present invention relates to compositions and methods for antibody-mediated immunity against viral targets. In particular, provided herein are engineered immunoglobulins with anti-viral activity.

Engineered immunoglobulins with altered fcrn binding

The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.

Methods and compositions for combination immunotherapy

Methods and compositions for generating immune responses using adenovirus vectors that allow multiple vaccinations or in combination with other therapy and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin

The present invention is directed to: a gene fragment which includes a DNA sequence coding for an amino acid sequence of a constant region of a feline immunoglobulin .lambda. chain; a gene fragment which includes a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglubulin K chain; a gene fragment which includes a DNA sequence coding for the constant region of feline immunoglubulin .gamma. chain; a recombinant DNA molecule coding for an amino acid sequence of a mouse-cat chimeric antibody which includes a gene fragment coding for an amino acid sequence of a variable region of a mouse immunoglobulin and a gene fragment coding for an amino acid sequence of a constant region of a feline immunoglobulin wherein the latter gene fragment is linked to the 3' site of the former gene fragment; a polypeptide of a mouse-cat chimeric antibody which is expressed from a cell transformed with an expression vector for cells wherein the recombinant DNA molecule coding for an amino acid sequence of the mouse-cat chimeric antibody is incorporated; a cat-mouse heterohybridoma which produces feline immunoglobulin; and a process for preparing a feline immunoglobulin gene. These products and processes can be used for the diagnosis, treatment and prevention of feline diseases.

Method of promoting an immune response with a bispecific antibody

A method of inducing an immune response in a patient is provided. The method involves administration of bispecific molecules capable of recognizing and binding FcγRIII and a second antigen. The second antigen may be a cancer antigen, a viral antigen, a fungal antigen, a bacterial antigen or a toxin. The second antigen may or may not be present in the patient at the time the method of the invention is performed.

Cytomegalovirus antigens and uses thereof

This disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins.

Adeno-associated virus antibodies and fragments thereof

The present disclosure relates to an isolated anti -AAV (adeno-associated virus) antibody or an antigen-binding fragment thereof capable of specifically binding an epitope of AAVrh74 capsid protein and uses thereof.

Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases

The present invention pertains to antigen recognizing constructs against antigens of the Merkel cell polyomavirus (MCV). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the infected host cells and tumor cell expressed MCV derived antigens. The TCR of the invention, and antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Circovirus sequences associated with piglet weight loss disease (PWD)

The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

Circovirus sequences associated with piglet weight loss disease (PWD)

The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

Circovirus sequences associated with piglet weight loss disease (PWD)

The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

Immunogenic compositions for immunization of pigs against circovirus type 3 and methods of prduction and application thereof

Изобретение относится к биотехнологии. Описана композиция для индукции иммунологического ответа против цирковируса свиней типа 3, содержащая: по меньшей мере один белок цирковируса свиней типа 3, причем указанный белок кодируется нуклеотидной последовательностью, имеющей по меньшей мере 90% гомологию последовательности с последовательностью, выбранной из группы, состоящей из SEQ ID No.3, SEQ ID No.5, SEQ ID No.7, или в которой указанный белок имеет по меньшей мере 90% гомологию последовательности с последовательностью, выбранной из группы, состоящей из SEQ ID No.4, SEQ ID No.6, SEQ ID No.8, или любой их комбинации; и ветеринарно приемлемый носитель, выбранный из группы, состоящей из растворителя, дисперсионной среды, покрытия, стабилизирующего агента, разбавителя, консерванта, противомикробного агента, противогрибкового агента, поддерживающего изотоничность агента, агента, замедляющего адсорбцию, или любой их комбинации. Также описана композиция для индукции иммунологического ответа против цирковируса свиней типа 3, содержащая нуклеотидную последовательность, выбранную из группы, состоящей из: а) нуклеотидной последовательности, выбранной из группы состоящей из SEQ ID No.1, SEQ ID No.3, SEQ ID No.5, SEQ ID No.7, SEQ ID No.9 или одного из их фрагментов; b) гомологичной нуклеотидной последовательности, имеющей по меньшей мере 80% идентичности с последовательностью, определенной в а); c) комплементарной нуклеотидной последовательности или последовательности РНК, соответствующей последовательности, определенной в а) или b); d) нуклеотидной последовательности, модифицированной последовательностью, определенной в а), b) или c); и e) рекомбинантного вектора, содержащего нуклеотидную последовательность, определенную в а), b), c) или d); и дополнительный компонент, включающий ветеринарно приемлемый носитель, выбранный из группы, состоящей из растворителя, дисперсионной среды, покрытия, стабилизирующего агента, разбавителя, консерванта, антибактериального агента, ...

Production and use of monoclonal antibodies against adenoviruses

Monoclonal antibodies, and a cell line characterized by its production of such monoclonal antibodies, demonstrating specific reactivity to an antigenic determinant possessed by a plurality of types of adenoviruses, a method of isolating such cell lines, and the use of such antibodies for diagnostic and therapeutic purposes as well as for identifying chemical compounds with similar properties, are disclosed.

Conjugates for introducing nucleic acid into higher eucaryotic cells

Conjugates in which a virus is bound via an antibody to a substance having an affinity for nucleic acid, for transporting gene constructs into higher eucaryotic cells. Complexes of the conjugates and nucleic acid are internalized in the cell, whilst the virus as part of the complex brings about the internalization and the release of the contents of the endosomes, in which the complexes are located after entering the cell. Pharmaceutical preparations in which the nucleic acid is a therapeutically active gene construct, particularly for use in gene therapy.